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One currently active area in cancer chemotherapy involves the study 
of drug transport across membranes. 20 ,57 ,82 . Conceptually, the phenom-
enon of membrane penetration by a medicinal agent could be potentiated 
by complex formation with another molecule which in turn could alter the 
membrane 1 s structure, at least temporarily, to permit a more rapid move-
ment of the medicinal agent or the complex into a cell. One theory for 
the structure of membranes includes a monolayer (a lipid bilayer could 
behave similarly) of phospholipids held together by a highly ordered 
water layer. 2o, 57 ,82 Also present in the membrane structure are usually 
protein and glycoprotein molecules among others. A hypothetical mem-
brane surface (a monolipid layer is illustrated but the theory could be 
applied to a bilayer system for which there is also considerable evi-
dence} is provided (Scheme 1) to illustrate a possible mechanism by 
which potentiation of activity of a medicinal agent might occur via 
complex binding to a protein on the membrane surface. 
A molecular complex is depicted between a medici~al agent and a 
heterosteroid (or related model heterocyclic compound) which we shall 
discuss shortly. 11 0rdered water11 near the membrane surface is a 
generally accepted postulate based on much physical evidence resulting, 
however, from in vitro studies. Some recent dielectric measurements of 
1 
Complex 
6. ~ f:::. D.f:::.6666 G. = glycoprotein 
fl r1r1rl1 p = protein 0 = -P0 3-
\l\l\l V'\l\l\7\l \l t> = H'o· H ... " 
t IM.A.I= medicinal agent ~= h eterosteroid 
or 
:@::~ M.A_J heterocycli c 
model com pd. 
G. p 
\l '\7 '\/ \l \l \l \l \! 
Penetration of membrane by complex (or by the medicinal 
agent). 
Note increased fluidity in lipid layer. 
Scheme 1. 
2 
membranes suggest an apparent thickness of water layers adjacent to mem-
branes of up to 40,000 A (4 µ thick). 37 The value may be too high but 
the data support also a 11 rigidity and orderliness 11 of water near the 
membrane. If the heterosteroid possessed a highly polar group, which we 
shall call a "hydropolar head", it is not unreasonable that this group, 
if properly positioned on the membrane surface (e.g., bound to a protein 
3 
or glycoprotein) alone or in the complex, could through perhaps dipole-
dipole repulsive interactions disrupt the 11 ordered water" to permit a 
temporary "increased fluidity" in the lipid layer. 42 Thus the medicinal 
agent or the complex could penetrate the cell more rapidly and 
efficiently. Consequently, a possible ramification of complexation 
studies would be to determine the parameters in a heterocycle which 
could ultimately promote ea$y complexation with a medicinal agent and/or 
induce more efficient penetration of a cell. by a medicinal agent. The 
complexation could greatly prolong effective use of a drug before an 
organism developed re~istance to it so that massive amounts were 
required. Obviously, the latter is less than desirable since large 
doses of a medicinal agent can often have pronounced and adverse side 
effects. Finally, it is also conceivable that a 11 lipophilic head" and 
"hydrophilic head 11 in a molecule could improve cell penetration. This is 
currently being evaluated in our laboratory for systems as shown. 
ROg:> X, Y - heteroatoms [hydrophilic head] R = long chain [lipophilic hea~ 
The role of steroids in chemotherapy is well documented but the 
structure-activity relationship of heterosteroids is a relatively new 
area. 41 , 143 Assuming that a heterocycle (such as a heterosteroid) could 
form a molecular complex with a medicinal agent and this complex could 
bind to the surface of a membrane (perhaps through complexation with a 
protein2J,BO via hydrogen bonding, a charge-transfer mechanism, or TI-TI 
overlap or a combination thereof), one can envision the initial struc-
ture of complex-membrane as shown in Scheme 1. Of course, the 
stability of such a complex would likely be of paramount importance 
since the medicinal agent must presumably exist at least partially free 
to be effective inside the cell. A study of the equilibrium process 
forming a complex between an anticancer agent and a heterosteroid is 
needed but selection of examples is likely to be critical if a correla-
tion is to be investigated between K and biological activity. . eq 
4 
The use of heterosteroids offers the novel opportunity to form 
charge-transfer complexes with medicinals, a situation not commonly pos-
sible with many naturally occurrinq steroids since most do not possess 
heteroatoms such as N or S which permit ready electron transfer. Inter-
actions of this type between compounds and biologically important sub-
stances, such as proteins, are rare but known in the literature. 
Similarly TI-TI overlap and hydrogen bonding between substrate and certain 
molecules at a reactive site are also documented although, to be sure, 
the data are based primarily upon analogies to .!D.. vitro systems rather 
than in vivo results. On the assumption that heterosteroids and 
st~ucturally related systems could provide drug potentiation (possibly 
through the mechanisms described above) or separate and unique activity, 
considerable effort has been initiated within the past 6 to 8 years for 
developing syntheses for such molecules. A molecular complex between 
actinomycin D and 10,ll-dihydro-3H-naphth[l,2-iJ indazol-7-ol (g) has 
been studied via PMR, UV, and fluorescence spectroscopy. 43 ,44 Although 
the molecular complex was eight times as effective as actinomycin D 
alone against Bacillus subtilis, the potentiation factor fell to about 
1.04 in mice. The field of chemotherapy using heterosteroids is only 
5 
I a R = H ,_ -
J?, R = CH 3 
RO 
i.n its infancy, and it will require considerable synthetic finesse to 
design and prepare structures capable of improving drug efficiency with 
minimum toxicity. This theory of potentiation can obviously be related 
to the 11 synergism theory 11 , and the role of synergism in chemotherapy has 
been recognized for many years but not completely understood. Moreover, 
primary screening processes of mixtures of two drugs in~· subtilis or 
even in animals may not give positive results, and yet the activity of 
such a mixture could be considerable in man. 
A molecular complex of actinomycin D and 5'-deoxyguanylic acid is 
known8 as is also the case with valinomycin and K+. 96 Both of the 
medicinals are important clinically. A synergistic effect was recently 
recorded for the increased life span of mice inoculated with L-1210 
ascitic tumor cells. 10 The magnitude of this synergism increased as 
the dosage of either cytosine arabinoside and methotrexate or both was 
increased. At maximum dosage (12 mg. methotrexate/kg. plus 1200 mg. 
cytosine arabinoside/kg.) the drug combination completely eradicated 
tumor cells of 11 of 40 mice and extended the mean survival of the 
remaining 29 animals by 23-64 days (up to 332%) beyond control survival 
( 7 + 1 days ) . 10 
An exciting related area involves complexes of medicinal agents 
with antibodies in cancer chemotherapy. 51 It seems quite reasonable 
that some of the molecular forces maintaining the integrity of such 
6 
complexes must be those discussed above for heterosteroids or simpler 
heterocycles. For example, the ease with which many hallucinogens and 
tranquilizers affect higher organisms make related heterocyclic systems 
worthy of cautious examination. Mescaline {.f) and related compounds i-.§ 




conceivably cross membrane barriers in certain cellular systems35 and 
yet closely related heterocyclic model systems have not been systemat-
ically investigated for possible complexation with or potentiation of 
activity of clinically used anticancer agents. The area appears ripe 
for study but will need synthetic organic chemists and biochemists 
collaborating to be fruitful. 
Polymethoxy-substituted compounds are widely distributed in the 
field of natural products. A few representative alkaloids recently 
isolated containing three or more methoxy groups are shown in Figure 1; 
some other recently isolated natural products containing polymethoxy 
groups are shown in Fi·gure 2. 
Many polyalkoxy compounds synthesized display biological activity. 
There has been a considerable amount of work on 3,4,5-trimethoxyphenyl-
substituted compounds of possible psychotropic activity. 122 At first 
appearance, these compounds have little chemical relationship except the 
possession of 3,4,5-trimethoxyphenyl groups. Recently synthesized com-
pounds containing such a group are the benzoyloxazolidine .§., 4-(3,4,5-
CH30 'r()'TJ.H 
CH 30~N 
· CH30 C02H 
0-methylpeyoxylic acid77 
(Trace constituent of peyote) 
Tylophorine58 (Major alkaloid 
from Tylophora asthmatica) 
~:CH3 
CH 30 CH 3 
l,3,5-Tr1~5thoxy-10-methyl-






(Trace constituent of peyote) 
7 
1,5,6-Trimethoxy-I4~-methylenedioxy-
10-methyl acri done (I so 1 a ted from 
the bark of Teclea boiviniana) 
OCH3 
OCH3 
Capaurine89 (Constituent of four 
plants) 
Figure 1. A Few Representative Alkaloids Containing 
Polymethoxy Functions 
0 
CH30~· OCH3 0 I 
CH30 CH CH 
HO 2 3 
Lomandrone36 (A pigment in Lomandra 
hastilis) 
0 
Lomastilone36 (A pigment in 
Lomandra hastilis) 
Coleen s116 (A yellow dye of Coleus . 5,6,7-Trimethoxyflavone90 
igni~rius leaf glands) (Isolated from Kichxia 
lanigera) 
5,6,7,4'-Tetramethoxyflavone90· 
(Isolated from Kichxia 
lanigera) 
Lyoniresiono1 124 (Isolated from 
heartwood of Ulmus thomasii) 
Figure 2. Some Natural Products Containing 
Polymethoxy Functions 
8 
trimethoxythiobenzoyl)morpholine (7), and five other 3,4,5-trimethoxy--
benzamides, which were screened for central nervous system depressant 
activity in mice. 111 Compounds ..§.and l depressed conditioned avoidance 
9 
behavior and exploratory hypermotility. Antibiograms confirmed the 
sensitivity of group A streptococci towards a new chemotherapeutic agent 
Eusaprim (drug trade name) containing trimethoprim (~) and sulfameth-
oxazole.139 Papaverine (2) given to anesthetized cats decreased arterial 
pressure and blood flow in the renal and superior mesenteric veins, 
increased blood flow in the coronary sinus and sagittal sinus of the 
brain, and had a biphasic effect on femoral vein flow. 1 Six 2,4-
diamino-5-(3,4,5-trimethoxybenzyl)-6-(arylsulfonyloxy)pyrimidines (lQ) 
showed bacteriostatic activity on Streptococcus hemplyticus, f. coli, 
Pseudomonas pyocyanae and Staphylococcus pyogenes aureus. 47 trans-8-
(3,4,5-Trimethoxystyryl)caffeine OJ) is now beinq evaluated for use 
as a cerebral stimulant. 110 
10 
.!.Q R = H, CH 3 , Cl, Br, 11 
CH;f(O)NH, 
C2H5 C(O)N H 
The alkaloid cryptopleurine (!S), a natural product from Boehmeria 
cylindrica, has a significant cytotoxic effect against Eagle's 9KB 
carcinoma of the nasopharynx in cell culture and is responsible for part 
of the antiviral activity observed in tests with crude extracts of B. 
cylindrica. 85 In screens to determine the inhibitory mechanism of 
CH30 
CH 30 CH30 CH30 
12 





tylophorine (!].) and tylocerbrine (14), inhibitors of 80s-type ribosomes, 
it was shown that there was possible binding to the 80s ribosome and the 
60s subunit; 15 emetine (!.§) showed no antibiotic binding in the same 
tests. 15 Thalicarpine (!§),a tumor-inhibitory aporphine benzyliso-
quinoline alkaloid, has recently been synthesized. 87 
Parkhurst and co~workers 105 have reported the synthesis of some 
benzocycloheptane derivatives and the results of preliminary screening 
for pharmacological activity in mice. All these compounds are 
benzocycloheptane derivatives with methoxy and/or hydroxy substitution 
on the benzene ring. Substitution of OH for OCH3 at R in most of the 
compounds had little effect on activity. Also noted was a lack of 
enhancement of depressant activity. In one case, a stimulant response 
in mice was noted OZ.~) while the hydroxy derivative 17ad produced a --
depressant behavior. 
R = 2. -OH 
,2. -OCH3 
17 
RI -- 0 ~ = 
.c! =NNHC(O)NH2 
~ =NNHC(S )NH2 
1 =NOH 
,2. -NH2 , H 
J:!. -NHCOf H3 , H 
The alkaloid colchicine (!§.) has long been known to be a mitotic 
poison. 56 It recently has been reported that a 1% solution of 
colchicine caused chromosome doubling in the green alga Oedogonium 
acmandrium. 120 Preliminary results indicate that the methyl ether of 
thiocolchicine (1,2) shows greater cytotoxicity against L-1210 leukemia 
than colchicine;61 other alkyl ethers of thiocolchicines showed lower 
activity in the same tests. 61 
12 
b·NHC(O)CH 
3 II· NHC{O )CH3 
0 
Zee...:Cheng and co-workers 155 reported the preparation and activity 
against leukemias L-1210 and P-388 of several alkoxybenzophenanthridinuim 
salts. It was found that ~ and ~ showed greater antileukemic activ-
ity than Coralyne {20b); 20d was virtually inactive. -- -
Protoberberine derivatives~-£ were prepared by Kametani 76 by 
reaction of ~ with the corresponding acid. These derivatives were 
useful as analgesic, vasodilating, and hypotensive agents. 
CH 30 
R -H = 1!. 
CH 30 .!?. -CH3 
£. -C2H5 
d -(CH 2)2 CH3 
OCH 3 
20 OCH3 -




£ -e-CH3c5H4 so2o 
21 OCH 3 d .. H -
13 
The synthesis of compounds having poly(lower alkoxy)estrane struc-
tures was first reported by Axelrod, Rao, and Baeder. 12 Compound~ 
was obtained by two different methods. In the first approach 17S-
acetoxy-2-methoxyestra-1,3,5(10)-triene 3-(2'-benzoyl-4'-nitrophenyl) 
ether 22a was allowed to react with concentrated sulfuric acid to give -








and the crude product was treated with diazomethane to 
aryl group in 22b was removed by boiling with piperidine -
to give 22c, which, when allowed to react with methyl sulfate and -
anhydrous potassium carbonate in acetone, gave 22d. Alkaline hydrolysis -
of 22d with lN methanolic KOH gave 2,3,4-trimethoxyestra-1,3,5(10)--
trien-17S-ol (22e). The second method to obtain 22e involved the -- -
reaction of 22f with 1 equiv. of concentrated nitric acid in acetic --
acid to give 22g. Diazomethane and nitro compound 22g reacted to give -.-. -....;;. 
Catalytic hydrogenation of 22h using Raney nickel catalyst gave -
14 
~- The amino compound~ was diazotized with sodium nitrite in 1:1 
acetic acid/ dioxane. A resulting crude phenol was methylated with 
dimethyl sulfate and anhydrous potassium carbonate in acetone to give 
~· Initial biological testing11 of 22~ indicated some analgesic 
activity when compared to some clinically active standard analgesics, 
but further laboratory testing 146 indicated the compound was devoid of 
pharmacologic activity. 
Roa and co-workers 114 reported the preparation of two isomeric 
hexahydro-6,7,8-trimethoxyphenanthrene-2a-carboxylic'acids 25 and 26 
from the Diels-Alder condensation of 3,4-dihydro-5,6,7-trimethoxy-1-
vinylnaphthalene (~) with methyl acrylate (Scheme 2). Acid£§ isomer-
ized to ~ in the presence of acid. Both £§ and £§ gave the same 
octahydrophenanthrenecarboxylic acid J1 on reduction with a limited 
L 
Scheme 2 
quantity of Na and liquid NH3. No biological screening data was 
reported for these compounds. 
15 
Rao, Jacob, and Axelrod113 reported the total synthesis of steroids 
containing a trimethoxybenzene ring. They initially described12 the 
synthesis of (+)-2,3,4-trimethoxyestra-1,3,5(10)-trien-17S-ol (Il) by 
two different methods from an (+)-estradiol, but the overall yield by 
these routes was low. Scheme 3 shows an improved route to I?113 and 
similar compounds. 3,4-Dihydro-5,6,7-trimethoxynaphthalen-1(2!:!)-one 
(~) was treated with vinylmagnesium bromide to give ~· Condensation 
of this alcohol ~with 2-methylcyclopentane-1,3-dione in the presence 
of Triton B afforded~ which, on boiling with £_-toluenesulfonic acid 
in benzene, cyclized to yield 2,3,4-trimethoxyestra-1,3,5(10)-8,14-
pentaen-17-one (~). Compound~ was then reduced with sodium boro-
hydride in methanol to give l!· Selective hydrogenation of the 14,15-
double bond over 2% palladium on calcium carbonate gave the tetraenol 
32. Completion of the synthesis of ~ involved stereoselective reduc-
tion of the styrenoid bond in ~ by metal-ammonia. Excess metal-ammonia 
gave the dimethoxy derivative ~· 
For the preparation of stereoisomers of (~)-2,3,4-trimethoxyestranes 
the pentaenone ~served as an ideal intermediate (Scheme 4). These 
compounds are presently undergoing examination for biological activity. 
Initial pharmacological tests indicated that ~ p·ossessed strong 
analgesic activity; how~ver, further testing revealed that the analgesic 
activity originally claimed was not reproducible. 113 
A number of physiologically active azasteroids have been reported 
and several reviews on this subject have been written. 4,84 ,92 ,128 ,129,137 
Recently the total synthesis of heterocyclic steroidal systems has been 
r X$8 Hfx) 0 
CH30~ MgBr CH:P OH o CH o .. 0 .. 3 0 
CH 30 CH30 CH30 
CH30 CH30 CH3o 
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reviewed by HuismanJl,72 Since this field has been reviewed through 
1970,99 only pertinent azasteroids reported in the 1971-1974 journals 
will be discussed here. 
Pyrazoles containing 2'-aryl substituents impart enhanced anti-
inflammatory activity when fused to the corticoid nucleus at the 2,3 
pas i ti ans. 60 17a,21-Di hydroxy-20-oxopregn-4-eno [3 ,2-~] -2' - ( 4-
fl uorophenyl) pyrazol e (4,Z) was 30 times as potent in local granuloma 
tests as hydrocortisone. 11S,17a,21-Trihydroxy-6,ll-dimethyl-4,6-
pregnadieno[3,2-~J-21-(4-pyridyl )pyrazole ('!§) exhibits high vasocon-
CH3 
:II' 




47 48 - N -F 
striction activity in human volunteers and is clinically effective in 
the treatment of psoriasis. 
18 
Rastogi, Chowdhury, and Enge1 115 recorded the first synthesis of 
11-aza-98-steroids, both in the spirostane and 3,20-dioxygenated pregnane 
series. They reported the' synthesis of fi-acetyl-11-aza-5a,9S-pregnane-
3,20-dione (~) and the 11-aza-98-spirostane §.Q. The synthesis of the 
3,20-dioxygenated-ll-azapregnane with 11 normal 11 (a) configuration in 
position 9 has also been completed. 34 No biological activity has been 




Several biologically active 17~azasteroids have appeared recently. 
The 17-azasteroids g and 53 were prepared141 by reducing their 16~oxo 
R 
25 ~ 
_g_ R = OCH2CH20, R 1= H, CH3, C2H5 R = H, c21-i5 , CH 2CH20H 
J? R =O, R1= CH3 
.£. R =H,OH, R1= H 
or 20-oxo derivatives with LiA1H4. Both~ and §1 were intermediates 
for bactericidal and hypocholesteremic steroids. Tuba and Bor142 
reported the preparation of the 17-azandrostanes ~ and the 17-
azaestratrienes ~ from the treatment of the free 17-azasteroid with 
ClCH2COC1 and then substitution of the other R". Members of 55 were -
catatonic, particularly against Icterus gravis neonatorum. The 
quaternary salts ~ have curare-like activity and the piperazinyl 
derivatives are antibacterial. 
RI 
54 ......... 
RR 1 =OCHfH20, =O 
R =H, R1 =OH 
R" = ~:~s~::c.c~KJ ~-
H3c 
The androstane derivatives !i§ were obtained140 by the Hofmann 
degradation of 16,17-~16,17-imides and optional alkylation with R11 
20 
of the 17-unsubstituted compounds. 
useful as bactericides. 
These androstane derivatives 56 are 
56 -
RR 1 = OCH2CH20, R11 = H 
R =OH, R1=H, R11 =H 
I II 
RR = OCH2CH2o, R = CH3 
I II 
RR = OCH2CH20, R = C2H5 
-
The synthesis 103 of the 8,11-diazasteroid skeleton is summarized in 
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Isoxazole and pyrazole derivatives can easily be made from the 
corresponding a-hydroxymethylene ketones. Hence from 64 the following ....... 
compounds were prepared52 (Scheme 6): benzo[b]thiochromano[3,4-g]-
23 
isoxazole (g§), benzo[bJ thiochromano[4,3-~] isoxazole (§§), and 
1-hydroxy-3~-benzo [b] thi ochromano [ 4 ,3-c;Jpyrazol e ( §2). Currently, 
biological screening data are unavailable. Likewise, the following com-
pounds were.synthesized from the a-hydroxymethylene ketone 72 (Scheme 7): ......., 
3g-hydroxy~4-methyl-7-methoxy-10,ll-dihydro-ti 1 -isoxazolinol5,4-il-
phenanthri dine (73), 4-methyl -7-methoxy-10 ,11-dihydroisoxazol o[5 ,4-i] --
phenanthri dine (74), and 4-methyl -7-methoxy-10, 11-di hydro-2~-pyrazol o-......, 
[3,4-i] phenanthridine (75). 91 -
Several 11-oxa-15,16-diaza analogues of equilenin have been synthe-
sized and screened by Kasturi and Arunachalam78 (Scheme 8), including 
the pyrazoles 81a, 8lb, 83a, and 83b, the isoxazoles 80a, 80b, 82a, and ,,......_, ,,.....,_, """" ,,...._,. ,,....._, ,,,,....._,, ,,,,,..._,, 
82b, and the pyrazolinones 86a and 86b. Surprisingly, none of these 
........_, .,..._. ----
showed any significant biological activity except the isoxazole 80b, -...... 
which exhibited weak antidepressant activity at an oral dose of 
300 mg/kg in mice. 
Bonnardeaux and Lematre19 studied the physiological properties of 
15,16-diazagonaheptene derivatives 87a-d in rats, rabbits, cats, and ,,,......._,, 
.2. R = H 
N' 
1?. R = C02H 
c R = co2c2H5 
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dogs. It was found that only those compounds which had a free carbonyl 
group in a position directly opposite to their phenyl function ~ere 
active. The main observed action was water retention concomitant with 
hypertension. 
Morgan, Berlin, Durham, and Chesnut reported the synthesis of the 
equilenin 15-azasterotd analogues 101 88a and 88b and the 15,16-diaza-
. ,,._ --.... 
equilenin derivatives 100 la and lb. 1,10,11,lla-Tetrahydro-lla-methyl-
RO 
~.e. R=H 




~ R = CH3 
2~-naphth[l,2-g]indol-7-ol (~) and l,10,ll,lla-tetrahydro-7-methoxy-
lla-methyl-2tl-naphth~,2-<J] indole (~) inhibited growth of KB and L-M 
cells in the culture. 67 The indazole lg exhibited .:i.!!_ vitro activity 
against a variety of microorganisms. 100 
A few 11 model 11 azasteroids with the A, C, and D rings only have 
recently shown biological activity. Watanabe and Ogata149 developed 
the synthesis of substituted naphth[2,l-d]isoxazoles such as 3-phenyl-
naphth[l,2-d] isoxazole-4,5-dione (~),which was found to be an effec-
tive fungicide against Colletotrichum lagenarium at 100 ppm, and sub-
stituted naphth[2,l-d]isoxazol-4-ones such as 3,3 1-diphenylspiro[l,4,2-
dioxazole]-5,51-(41tl)naphth[2,l-d]isoxazol-4-one (2.Q), which proved to 
be fungicidal against Sphaerotheca fuliginea at 500 ppm. Suzuki, Staya, 
and Minami 136 synthesized 3-substituted naphthisoxazoles 9la-d and 92 -
I II .fil .!! R = OCH3 , R = H, R = CH2co2H 92 
E_ R = R1= H, R11 = CH2C(O)NH2 
R RI H R11 -- co H 2. = = ' 2 
I II 2, R = CI , R = 0 C H3 , R = C o2 H 
which were found to be antiinflammatory, analgesic, antipyretic, and 
anti rheumatic. 
There are many pyrimidines of biological and medicinal interest. 
28 
Cheng has recently reviewed this topic extensively. 28 ,29 ,30 Of several 
5-benzyl-2,4-diaminopyrimidines that were synthesized and tested for 
antibacterial activity, 119 2,4-diamino-5-(3,4,5-trimethoxybenzyl)-
pyrimidine (§),also known as trimethoprim, was the most effective 
against both Gram-positive microorganisms and Gram-negative bacteria. 
Compound 8 was later reported28 to produce a rapid clinical remission ,., 
in all cases of infection with both 11 normal 11 and a chloroquine-
pyrimethamine-resistant strain of PlasmodiLim falciparum in human beings. 
29 
Cl 
It is the only compound so far reported that produces positive responses 
in human malarias but not inf_. berghei infections in rodents. 112 
5-Piperonyl-2,4-diaminopyrimidine (93), which is closely related in .,..,, 
structure to trimethoprim (§) and the antimalarial compound pyrimethamine 
(94), combines the therapeutic effect of the former against chloroquine-....... 
resistant strains of P. falciparium with the prophylactic and therapeutic 
effects of the latter. Compound ~ is effective against ~· berghei at 
dose levels where 2? is void of activity, and it does not depress cardiac 
function as do the two parent compounds. 112 
The nature of structure-activity relationships of compounds is an 
enormously complicated problem although Hansch has developed a working 
semiquantitative theory. 62 The binding of the drug to the receptor is 
of critical importance. 82 In general, bonds formed between a drug and 
a receptor are relatively weak so that the reaction produced is revers-
ible; that is, the drug-receptor bond is cleaved and the drug ceases to 
act as soon as its concentration in the extracellular fluids decreases 
sufficiently. This is exactly what is sought when pharmacodynamic 
agents are involved so that the response caused by the drug will last 
for only a limited time. Types of binding which have generally been 
• 
30 
considered important to drug-receptor interactions are: ionic attrac-
tion ( 5 to 10 kcal/mole), ion-dipole or dipole-dipole interactions ( 1 
to 7 kcal/mole), hydrogen binding ( 1 to 7 kcal/mole), charge transfer 
( 1 to 7 kcal/mole), hydrophobic interactions (~ 1 kcal/mole), and van 
der Waals forces ( 0.5 to 1 kcal/mole) between electrons of one atom 
and the nucleus of another. 82 
An example of the drug-receptor complexation through ionic and 
secondary bonds has been suggested in local anesthetics and their 
respective receptor sites. Anesthetics have been tentatively linked to 
the receptor site by weak bonds, 117 which could explain why the effect 
produced was reversible and of only short duration. 
The presence or absence of biological action in certain compounds 
is ascribed, in some cases, to the capacity for forming or not forming 
hydrogen bonds. This fact influences their physiochemical properties 
and hence their pharmacodynamic activity. 1-Phenyl-2,3-dimethyl-5-
pyrazolone (antipyrine) (95), which is soluble in water and moderately 
~ 
soluble in ether, has analgetic properties; its partly demethylated 
analog, 1-phenyl-3-methyl-5-pyrazolone (96), being insoluble in water 
and only slightly soluble in ether, has no analgetic activity. This 
discrepancy may be attributed to the fact that the former compound does 
not form intermolecular hydrogen bonds, whereas the latter compound 
31 
does.40 
Baker postulates that there are two classes of donors and two 
classes of acceptors involved in charge-transfer complexes. Donors 
involved would be: a) those rich in TI-electrons (a·lkenes, alkynes, and 
aromatic compounds, especially those with electron-donating substituents) 
orb) those that have an unshared electron pair such as R-5:, R-~:, R-~:, 
I I .. 
H H 
R3N:, etc. (the same groups that act as proton acceptors in hydrogen 
bonds): Acceptors would be: a) those compounds deficient in TI-
electrons by containing groups that withdraw electrons very strongly and 
b) compounds with weakly acidic hydrogens, such as alkyl-0-H, Ar-0-H, 
R-S-H, etc. (the same kinds of molecules that act as proton donors in 
hydrogen bonding). 
Certain enzymes that interact with drugs have many nonpolar chains 
on their surfaces. Several drugs, likewise, possess nonpolar regions in 
their structures. These chains can be either aryl or alkyl. It is 
expected that hydrophobic forces intervene in the formation of macro-
molecule-drug complexes and that they can be of quite appreciable 
magnitude. 82 Van der Waals forces, although weaker than others that 
act in biological systems, are of utmost importance in the stabiliza-
tion of protein structures, because their interactions are much more 
numerous than the interactions of hydrogen bonds and ionic 
bonds. 94 
Orientation of the drug to the receptor could be of importance when 
multiple types of bonding are involved. A striking number of drugs con-
e 
tain certain atoms strategically positioned at a distance of about 55 A 
from each other, 109 which is the distance between two turns of the 
32 
a helix in proteins. The fact that the effective functional groups 
(hydroxyl and amino) are capable of hydrogen bonding suggests that the 
molecules of such drugs could attach themselves to proteins via hydrogen 
bonds. Consequently, a change could result in the native hydrogen bond-
ing arrangement and the shape of the protein molecules. Obviously, a 
great change in an enzyme's conformation at its active site could 
markedly alter its specificity. · Drug action could be the consequence 
of such alteration in an enzyme. 
Cheng and Zee-Cheng154 have noted a common structural feature among 
a number of anti leukemic agents. The empirical treatment of data con-
sists of a triangulation process involving distance between one nitrogen 
and two oxygen atoms. A few of the examples they cite are given in 
Figure 3. The triangular relationship process for several compounds has 
0 
revealed distances for a N-0 1 bond of 7.80 ! 0.56 A,~ N-0 2 bond of 
8.62 ! 0.58 ~' and an 01 -02 bond of 3.35 + 0.65 ~ (Figure 3).: Conceiv-
ably these distances are absolutely critical in the binding to one of 
the pertinent receptor sites in certain biopolymers (proteins, polysac-
charides, nucleic acids, etc.) involved in leukemia geneses. The posi-
tion of the three atoms could result in inhibition of the active sites 
of the enzymes, in alteration of the specificity of enzyme systems, in 
disturbance of the template molecules in the transcription process, in 
changing the permeability of certain biological membranes, or in causing 
other interruptions of biological functions. Of the 36 compounds Zee-
Cheng and Cheng mentioned, 29 were found to have antileukemic activity· 
and 7 did not. Twenty-seven (27) of the active chemicals showed a com-
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had other common features, but did not appear to nave a similar 
triangular relationship involving the heteroatoms. The triangular pat-
tern cannot be used to explain the antileukemic activity of hydroxyurea, 
ellipticine, and biological alkylating agents. 
Cheng25 reported another common triangular feature among certain 
antimalarial cinchona alkaloids [amino alcohols and 2-(p-chlorophenyl)-
2-(4-piperidyl)tetrahydrofuran]. Here each series of compounds is com-
posed of three parts: a planar (aromatic or heteroaromatic) ring, an 
oxygen-containing portion, and a nonplanar nitrogen-containing portion 
(Figure 4). Later he proposed26 a common structural feature among 
several classes of antimalarial agents involving three electronegative 
atoms (X1, x2, and x3) each possessing at least one lone pair of 
electrons, such as nitrogen, oxygen, or sulfur (Figure 5). Additional 
work, perhaps molecular orbital calculations of preferred conformations 
of molecules and electron-density distribution on atoms, could be 
instructive to determine the significance of this preliminary work. 79 
As an example of this approach for diagnostic utility, Kier was able to 
propose a working hypothetical model, with representative muscarinic 
receptor sites, after determining the preferred conformations of acetyl-
choline, 1-(+)-muscarine, and Q-(-)-muscarone using extended Huckel - -
theory molecular orbital calculations. 80 This structural relationship 





Figure 4. Common Triangulation in Antimalarial Alkaloids 
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2-[4-D.i ethyl amino,.. (1-methyl butyl)-
amino] -1,4-dimethoxynaphtha 1 ene 
Figure 5. Common Triangulation in Several Classes 
of Antimalarial Agents 
CHAPTER I I 
RESULTS AND DISCUSSION 
Objectives of this research have been many-faceted with regard to: 
the synthesis of compounds combining heterocyclic ring functions and a 
trimethoxyphenyl group, the type of and distance between heteroatoms in 
the compounds prepared, and the structure-activity relationships in 
these sytems as determined with microbial and tissue culture screens. 
We have been able to develop preparative methods for the following 
heterosteroids and model compounds. 
2J R =OCH3 , R1 = H, 
~ R = H , R1 = OC H3 , 
99 R = OCH3 , R1= H , -
100 R = H, R1=0CH3 , -
X = NH 
X =NH 
X =O 





!Q.! R = 0 c H 3 , RI= H , R11 = H 
~ R =OCH3 , R1= H, R11 = CH3 
~ R = H, R1=0CH3 , R11 = CH3 
105 R =SH 
36 
106 X = NH -- 108 -
107 x = 0 
Distances and angles between heteroatoms were calculated for the 
pyrazoles 97, 98, and 106 and the isoxazoles 99, 100, and 107 using 
,.._ ....._. ----- -- -...... 
x-ray diffraction data of similar types of compounds. The dimethoxy 
analogs (109 and 110) of the "model 11 pyrazole 97 and pyrazolosteroid - - -
37 
!.Q9 were available in our Laboratory64 and were included in the calcula-
tions, biological screening, and structure-activity correlation studies. 
Also included was the thiazole 111 because of its pronounced effect in -
110 __, 
the tissue culture screens. Results of these calculations are shown in 
Tables XII, XIII, XIV, and XV. 
Primary screens of all products were initiated with growth studies 
of Bacillus subtilis W23 and Pseudomonas fluorescens NND. These data 
were obtained in part in this joint project by members of Dr. Durham's 
research group in the Department of Microbiology. Table X contains the 
results of these activity screens. It is interesting that the most 
38 
consistent inhibition of growth was observed with the pyrazoles. 
Because of this activity, the pyrazoles were evaluated for their ability 
to inhibit cell plating efficiency of the human tumor cell line - KB. 
Results of the tissue culture screens are given in Tab 1 e XI. 
A comparison of the distances and angles between heteroatoms and 
the percent plating efficiency of KB cells in the presence of the com-
pound was made. Figure 10 suggests that, at least in the compounds 
. 01 -N which have been tested to date, the closer the value of the ratio 02_N 
is to unity, the less inhibition is observed. The greater the 
deviation from one of this ratio, the greater the inhibition. One can 
certainly speculate that the distance between two or more active sites 
on the biological substrate could be related to distances between the 
heteroatoms in our compounds as has been suggested in other drug-receptor 
systems. 82 In the cases examined (which to be sure are fewer than 
desirable from a statistical basis) no obvious correlation is apparent 
between the 01-N-02 angle (as calculated from the triangulation 
process) and percent plating efficiency (see Figure 11). 
Synthetic Techniques 
The method of synthesis for 5,6,7-trimethoxy-3,4-dihydro-1(2~)­
naphthalenone (g§) (one of the key starting tetralones) was recently 
optimized. 132 Classical methods of Haworth,65 i.e., Friedel-Crafts 
succinoylation and Clemmensen reduction followed by cyclization,involved 
several difficulties. However, the general approach has been applied 
successfully by many workers to the preparation of ~ but in less 
yield. 65 ,89 ,98 Methoxy group cleavage (the group was usually in the 
ortho position) 6S,?0,89 ,98 was a common side reaction in Friedel-Crafts 
39 
reactions involving these types of compounds making isolation of prod~ 
ucts and purification difficult. Moreover, the major product from the 
reaction was the 5-hydroxy derivative of 28 which had to be remethylated. -0 
In our hands the use of 3-carbomethoxypropanoic acid and 115% PPA under 
11 succinoylation conditions 11 with 1,2,3-trimethoxybenzene (Scheme 9) 
circumvented thts problem and provided the necessary intermediate ill 
in good yield without the production of a mixture of methylated and 
partially methylated products. Hydrogenolys is of aryl -substituted 
ketones over Pd/C has been an efficient method for reduction to the 
corresponding hydrocarbons. 23 By utilizing lower reaction temperatures 
and longer reaction times in the cyclization of !..!.§with PPA, Snider 
and co-workers 132 minimized the problem of methoxyl ~leavage which had 
been reported in this type of reaction. 75 
Owing to the efficiency of each step, the reduction, saponification 
and cyclization process to yield the final product was realized in an 
overall yield of> 80% for 28 (based on 114) without isolation and - -
purification of ~intermediates. This compares to a yield of 60-70% 
of demethylated 28 fro~ the keto ester 115 via the more classical - ---
methods of Haworth previously alluded to. 
It was found that when 3-carbomethoxypropanoic acid 113 was con--
verted to the acid chloride U§ which was allowed to react with ill in 
the presence of PPA (Scheme 9), the reaction time was shortened consider-
ably (45 min. vs. 2.5 hr. when the acid itself was used). However, 
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The other key tetralone 1l§ was prepared by a mJltistep sequence 
starting from gallic acid (117) as showed in Scheme 10. Trimethyl-__, 
41 
gallic acid (118) was obtained by treatment of 117 with dimethyl sulfate ........ -
in the presence of base. 93 The acid chloride !.!2 was treated in a 
classic base-catalyzed acetoacetic ester synthesis81 to form ethyl 
3,4,5-trimethoxybenzoylacetoacetate (J1.Q). Following deacylation of 
!f9 by ammonium chloride, the a-keto ester ~ condensed with ethyl 
bromoacetate (sodium ethoxide) to form the diester 122 which, upon --
boiling with 20% sulfuric acid for 45 hr, 66 gave .the y-keto acid ill· 
Reduction of the keto function with hydrogen in the presence of 10% 
Pd/C and cyclization of 124 in PPA produced the key tetralone 125. - --
According to the literature, polyphosphoric acid (PPA) may function 
simultaneously as a protic acid, a Lewis acid, and a phosphorylating 
agent. 6 Thus in the cyclization of y-phenylbutyric acid(!£.§), protona-
tion or the formation of a mixed anhydride 127 is postulated as the ---
initial stage (as shown in Scheme 11) in the formation of 1-tetralone 
(128). 86 --
Phenanthrone !l! (the key starting material for the synthesis of 
the heterosteroid systems 106, 107, and 108) was synthesized from -- ...._ -
tetralone 28 by initial condensation with methyl y-bromocrotonate in a 
~
Reformatsky reaction. This was followed by dehydration and isomeriza-
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butyric ester 129 which was saponified in aqueous potassium hydroxide. --
The resulting acid 130 cyclized in the presence of PPA to form 131 -- . ---
(Scheme 12). This identical procedure has been used for the formation 
of 3,4-dihydro-7-methoxy-1(2!:!)-phenanthrone (~)lOO from 6-methoxy-
1-tetralone (132) and 3,4-dihydro-6,7-dimethoxy-1(2.!:!)phenanthrone 








One unexpected aspect of this synthesis in the case of trimethoxy-
substituted phenanthrone !1.! was the difficulty in purification of the 
final product. Cyclization with PPA yielded a black tar. Passing this 
material through a column of neutral alumina (C6H6) followed by sublima-
tion of the product gave only a low yield (7.9% based on~) of !l!· 
In contrast, in the case of ~' simple chromatography of the reaction 
mixture on an alumina column provided pure 134 (18.6% based on 132). 99 - -
0 
CH30r§O 
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Phenanthrone ill was purified by Soxhlet extraction with .!!_-heptane in 
fair yield (30.8%). 64 
46 
A comparison of melting points of the various phenanthrones reveals 
a very interesting phenomenon. The monomethoxy phenanthrone 12.1 is 
reported to melt at 98-100°; 99 the dimethoxy phenanthrone 135 melts at ,......._ 
210-211°. 64 Interestingly, the trimethoxy phenanthrone !1_! melts at 
137-138°. Possibly a higher order of symmetry in phenanthrone !1.§ could 
cause such deviation from the expected increase of meiting point as the 
molecular weight increased. A different trend may exist in the case of 
the tetralones: 6-methoxy-1-tetralone (132) melts at 78.4-79°; 134 6,7----
dimethoxy-1-tetralone (133) melts at 99-100°; 64 5,6,7-trimethoxy-1-,.._ 
tetralone (~)melts at 74.5-76°; 132 and 6,7,8-trimethoxy-1-tetralone 
(125) melts at 124-125°. 65 No intuitively obvious explanation is -
available to explain this trend since tetralones 132, 133 and 125 show - ----- ,,___, 
an increase in melting point with an increase in mole~ular weight. 
Tetralone 28 seems to be the exception to the rule in this case; yet, ,,.._, 
it would seem to be more symmetrical than its isomer 125. ----
2,4-Dinitrophenylhydrazone derivatives 136, 137, and 138 were made ,...__ ......._,,. ,._,_,. 
for each tetralone and the phenanthrone 131. Several other derivatives ,_ 
were prepared from 3,4-dihydro-5,6,7-trimethoxy-1(2H)-naphthalenone (28) - ~ 
by classic techniques 50 ,126 ,127 (Scheme 13), including the oxime 139, .........,, 
methoxime 140, and thiosemicarbazone 141. Each compound was character-___. ,,......,_ 
ized by IR, NMR, and either elemental data obtained or the value for the 
molecular ion {peak-matched), on the mass spectrometer (Tables V, VI, 
and IX). Microbial screening was also obtained (Table X). None of the 
derivatives showed appreciable activity, unfortunately. 
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Treatment of the tetra lone ~or ill or the phenanthrone ill with 
ethyl formate in the presence of sodium methoxide gave the correspond-
ing hydroxymethylene derivative 142, 143 or 144. It is recognized that - -- ,......._. 
many tautomeric forms of this type of compound could exist. Terinski 
and Kozluk138 studied the direction of enolization in several a-formyl-
cycl anones (Scheme 14, !!. = 3 - 7). When forms 146 and 147 were examined - -
146 -
Scheme 14 
by NMR, IR, and UV analysis, it was found that the amount of the keto-
hydroxymethylene compound !£ decreased in the order c5 > c7, c8 > c6 > 
c9. This suggested initially that the hydroxymethylene derivatives in 
our work exist primarily in the enol-aldehyde form !!§ since the ring 
size involved contains six carbons. However, it is interesting to note 
that there is only one carbonyl absorption in the IR spectra of the 
hydroxymethylene compounds (which corresponds to the keto function) and 
a definite hydroxyl absorption (Table V). This seems to indicate that 
the keto-hydroxymethylene compound form may predominate in our struc-
tures in the solid state. This might be the result of conjugation with 
the adjacent aromatic ring. Although it is recognized that both 
tautomeric forms are conjugated, only one form contains an OH group. 
Treatment of the hydroxymethylene derivatives with > 95% hydrazine 
in methanol produced the pyrazoles in good yield (Schemes 15 and 16). 
Since two isomeric forms were possible, the NMR spectra were carefully 
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the NMR spectrum (DMS0-~6 solvent) showed a triplet (JHH = 0.7 Hz) at 
H 
6 7.52 (lH) which was assigned to the lone =C~ proton. 91 A broad singlet 
at 6 12.70 was assigned to the -NH proton. In all three cases the pyra-
zoles prepared showed a singlet for =CH (2_Z, c 7.33; ~' c 7.41; !Q,6, 
o 7.43, see Table VI) and a higher field signal for the -NH proton [~, 
c 7.40-7.76 (bs); 2.§, c 8.78-9.02 (bs); !Q§, c 7.47 (s)]. Pyrazole ~ 
showed a slightly lower field shift, probably because of the methoxy 
influence at C(9). In view of these data, we tentatively concluded that 
the correct form for our pyrazoles was consistent for the lH form 
( .:n:;~) rather than the 2!!. form C:r:-~H ). An x-ray analysis 
would be helpful here. Both types of tautomers are reported in the 
literature3,22 ,78 ,88 but often little or no conclusive evidence has 
been given for the form reported. 78 ,88 
The isoxazole derivatives 99, 100 and 107 were prepared from the ....., ~ ~
corresponding hydroxymethylene compounds (Schemes 15 and 16} by the 
procedure of Guthrie and co-workers59 for the formation of the [2,3-d]-
isomer. This process involved heating (100°) the hydroxymethylene 
intermediate with hydroxylamine hydrochloride and sodium acetate in 
glacial acetic acid for 30 min. No attempt was made to obtain the 
[3,2-G]-isomer ( r:;'J) using hydroxyl amine hydrochloride in 
pyridine. 59 There is no reason to doubt that we indeed obtained the 
[2,3-g]-isomer as evidenced by the IR (Table V) and NMR (Table VI) 
data. 
Formation of the a-keto ester 148 from the tetralone 28 was sue--- -
52 
cessfully achieved by heating 28 in anhydrous dimethyl carbonate in the ......... 
presence of slightly less than two equivalents of sodium methoxide. 
When only one equivalent of sodium methoxide was used, primarily start-
ing material was obtained. Slight deactivation of th~ sodium methoxide 
due to long storage might be a critical factor in the amount of material 
needed for a successful reaction. Because no absorption for 0-H 
appeared in either the IR or NMR spectra (Tables \.' and VI) and a very 
definite doublet of doublets (lH) occurred in the NMR spectrum (6 3.47-
3.67, JHH = 6 Hz, JHH = 9 Hz), it would appear that little enolization 
occurred. This is somewhat surpriSing since, through enolization, the 
molecule would be completely conjugated. 
Treatment of the a-keto ester 148 with > 95% hydrazine in absolute ---
methanol yielded pyrazolone 101 (4,5-dihydro-6,7,8-trimethoxy-lH-
. __. -
benz[g]indazole) (34%). Because of the presence of tetralone g.§ in the 
crude a-keto ester 143 used in the reaction, the hydrazone derivative --
149 was formed. Characterization by IR, NMR and mass spectral analyses ---
53 
(Plates XI, XII and Table VIII} quickly identified ~and the expected 
pyrazolone was then isolated from the original filtrate. An intense 
absorbance at 2.95-4.70 µ in the infrared spectrum (Table V} and a broad 
singlet at 8 9.00-11.20 in the NMR spectrum (Table VI) indicated that 
some enolization occurs, as might be anticipated since a longer con-
jugated system is available in tautomer lOla. 64 --
0 OH 
... 
IOI IOI a -- ___,, 
Synthetic methods for 5,6,7,8-tetrahydroquinazolines have recently 
been discussed. 131 A widely employed method involves a base-catal~~zed 
condensation of amidine or amidine analogs with s~dicarbonyl compounds. 9 
Condensation of guanidine hydrochloride and methyl 1,2,3,4-tetrahydro-
~o + rYAoN'J:"v. R' Base"' 0 
R R 
5,6,7-trimethoxy-1-oxo-2-naphthoate (11§} in the presence of slight 
excess (more than two equivalents} of sodium methoxide produced 2-amino-
pyrimidine !Q1 after boiling (9 hr} in methanol (Scheme 17) .. 
Application of the same reaction conditions to 148 in the presence --
of thiourea did not provide the thiol analog. However, by changing the 
solvent to a higher-boiling alcohol (2-propanol) and increasing the 
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· [b]quinazolin-4-ol {!.Q§) (11.2%) was isolated. As is typical of 
pyrimidine derivatives, neither 104 nor 105 was appreciably soluble in 
. --- ,.._ 
many organic solvents, e.g., ether, benzene, and chloroform. However, 
partial water solubility hindered product isolation. Only after very 
slow neutralization of the reaction mixture with ac~tic acid (while 
cooling in an ice/H2o bath) could a solid product b~ obtained. 
From methyl 1,2,3,4-tetrahydro-6-methoxy-1-oxo-2-naphthoate (l§.9) 
(prepared from tetralone 132 and dimethyl carbonate) the corresponding ,...._, 
2-aminopyridimine 151 and 2 .. thiopyrimidine 152 were prepared (Scheme 18). 
. ,,__ : ___, . 
In both cases, methanol was used, and the reaction mixture was boiled 
(4 hr.). The difference in reactivity of the methyl ester 150 might be . ,....._, 
attributed to the slight inductive effect of the added methoxy groups in 
ester !.1.§. A proposed mechanism is presented in Figure 6. 
In one case the a-keto ester 148 was not isolated, but, in the 
presence of an additional equivalent of base, methyl iodide in methanol 
was added to form 153. 118 Likewise, 154 was prepared from the tetralone ,..__,.. ......._ 
125. Treatment of either 153 or 154 with > 95% hydrazine in methanol --- - __, 
yielded the corresponding pyrazolones 102 and 103 (Scheme 19). -- --
The pyrazolosteroid !Q§ was obtained in analogous steps (Scheme 
20). The phenanthrone 131 was converted to the a-keto ester 155 via -- . --
initial heating (15 min.) with dimethyl carbonate in the presence of 
four equivalents of sodium methoxide. Methanol was added and the 
reaction mixture cooled before methyl iodide was added. Heating (60°) 
!..§.§ with hydrazine in anhydrous methanol produced the pyrazolone J:.Q§. 
It is interesting that the yield of the steroid pyrazolone 108 was so -
much lower (32.2%) than the yield of either 102 (84.5%) or 103 (90%). - -
This might be partially due to a mass action effect (starting materials 
Go. 
for !.Qg being 10 times the molar quantities for l@), and perhaps to the 
solubility of the molecules {155 being less soluble in methanol than ........... 
153). ___. 
A listing of products, their melting points, and yields from 3,4-
dihydro-5,6,7-trimethoxy-1(2.!:!.)-naphthalenone (~) is given in Table I. 
An analogous listing of data is given in Tables II and III for 3,4-
dihydro-6,7 ,8-trimethoxy-1(2.!:!)-phenanthrone 010 and 3,4-dihydro-6,7 ,8-
trimethoxy-1(2!:!)-naphthalenone (~) respectively. Products and perti-
nent data for products from 6-methoxy-1-tetralone (lJ..?) are given in 
Table IV. As is typical in pyrimidines {!.Q1, 1:.Q§, J:EJ, and 18), all 
have very high melting points with decomposition. 
Characteristic IR peaks for each product are given in Table V. 
There is a distinct C-H (Ar-H) peak for each product at 3.40-3.45 µ. 
There is always a strong absorbance for the aromatic methoxy (Ar-OCH3) 
groups somewhere between 8.84 and 9.20 µ. The monomethoxy compounds 
show a weaker absorbance in this region as would be expected. 
The NMR chemical shifts and coupling constants of products are 
given in Table VI. A comparison of chemical shifts for the protons in 
the methoxy function(s) in 6-methoxy-1-tetralone (~), 6,7-dimethoxy-
l-tetralone {133), 5,6,7-trimethoxy-1-tetralone (28), 6,7,8-trimethoxy-- -
1-tetralone (125), and specific derivatives is shown in Table VII. At ---
the moment, unequivocal proton assignments cannot be made in the NMR 
spectra of any of the trimethoxy products. It is worthy of note that 
there appears to be no general pattern in the chemical shifts of the 
hydrogen atoms in supposedly related methoxy groups. In fact, in the 
pyrazolone ~ the protons of all three methoxy groups appear as one 
singlet. Expanding the sweep width to 250 Hz rather than 1000 Hz still 
resulted in only one singlet. Other proton assignments were in agree-
ment with the proposed structure. 64 
Mass spectral data for most compounds appear in Table VIII. All 
compounds analyzed exhibited a molecular ion corresponding to their 
61 
respective molecular weights. Several compounds were characterized by 
peak matching selected !!!.!'~values. These results are given in Table IX. 
Owing to the biological activity displayed by compounds ~' ~,67 
and la~lOG attempts were initiated to prepare similar compounds with -
la 88 ·a R = H 
__,, - -
J?. R = cH3 
a saturated and partially saturated B ring. Several procedures have been 
recorded for making intermediate~ from a-{6-methoxy-1-naphthyl)-
ethyl bromide (~).l3 , 73 ,l 5 l,l 52 Scheme 21 was proposed to involve 
the fewest steps of highest efficiency for the preparation of ~. 73 
Since m-methoxyphenethyl bromide (l2§) was not available commercially, 
it was synthesized. Employment of the entrainment method106 for making 
Grignard reagents and condensation of the Grignard from m-chloroanisole 
(~) with ethylene oxide led to crude m-methoxyphenethyl alcohol (!.21). 
Purification processes (column chromatography or spinning band distilla-
tion) were unsuccessful in separating the alcohol !2Z from 12§. 
Slightly crude alcohol !i? was treated with PBr3 via the method of 
Hooz and Gilani. 69 Gas-liquid chromatography indicated that the reac-
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INFRARED SPECTRA OF PRODUCTSa 
Cpd. ArC-H Characteristic Bands Ar-OCH3 Miscellaneous Bands 
28 3.42 (s) keto C=O, 6.00 (vs) 9.08 (s) 6.31 (s), 6.88 (vs), 
7.52 (vs), 9.90 (s), 
12.38 (m) 
139 3.43 (vs) N-OH, 3.10-3.25 (m) 9.00 (vs) 6.80 (s), 7.38 (vs), 
""'-"' 9.72 (s), 12.50 (m) 
140 3.45 (s) N-OCH3, 2.90-3.10 (w) 9.00 (vs) 6.88 (w), 9.55 (vs), ..--J 
9.80 (s), 12.50 (w) 
141 3.43 (w) N-C=S, 6.85 (vs) 9.01 (vs) 3.00 (rn), 3.12 (m), 
N 3.22 (m), 8.00 (s), 
11.80 (s) 
136 3. 45 ( w) NH, 3. 10 ( w) 9.00 (s) 7.51 (vs), 8.03 (m), 
Ar-N02, 6.22 (vs) 9.84 (vs), 11.96 (m) 
142 3.41 (s) OH, 2.75-3.10 (m) 9.15 (vs) 7.40 (w), 7.53 (w), 
keto C=O, 6.08 (vs) 8.83. (vs), 11.43 (s) 
97 3.45 (vs) N-H, 3.25 (s) 9 .10 (vs) 6. 80 ( s) ' 7. 12 ( s) ' 
9.65 (s), 12.68 (w) 
99 3.42 (w) C=N, 6. 45 (w) 9.12 (vs) 6.90 (vs), 7.14 (vs), 
8.,01 (s), 11.69 (s), 
12.59 (w), 12.80 (w) 
"'-I 
+::> 
TABLE V (Continued) 
Cpd. ArC-H Characteristic Bands Ar-OCH3 Miscellaneous Bands 
148 3.43 (vs) ester C=O, 5.78 (vs) 9.01 (vs) 6.30 (vs), 7.41 (vs), --- keto C=O, 5.99 (vs) 8.01 (s), 9.78 (s), 
11. 70 (m) 
101 3.43 (s) OH, NH, 2.95-4.70 (vs) 8.98 (vs) 6.28 (s), 7.61 (s), ,..._, 
9.63 {s), 13.10 (w) 
104 3.41 (s) NH, 2.85-3.15 (m) 8.97 (s) 7.11 (s), 8.03 (w), -- OH, 3.35-3.70 (m) 10.05 (w), 13.00 (s) 
C=N, 6.00-6.25 (vs) 
105 3.43 (s) OH, SH, 3.10-3.60 (w) 8.97 (vs) 6.45 (vs), 8.38 (vs), ,.._, 
C=N, 6.00-6.25 (vs) .> 10.15 (m), 12.04 (s) 
153 3.43 (s) ester C=O, 5.79 (vs) 8.95 (vs) 6.85 (s), 7.41 (s), -- keto C=O, 5.96 (vs) 8.01 (s), 9.28 (w), 
11. 60 (w) 
102 3.45 (s) OH, NH, 3.05-3.65 (s) 8. 95 ( s) 6.85 (s), 7.81 (s), 
C=O, 5.94 (vs) 9.60 (w), 11.96 (w), 
13.98 (w) 
130 3.43 (s) OH, 3.10-4.00 (w) 8.97 (vs) 7.60 (s), 7.82 (s), ........., 
acid C=O, 5.83 (vs) 12.17 (s) 
131 3. 44 (w) keto C=O, 5.98 (vs) 9.06 (vs) 6.79 (vs), 8.00 (vs), ___, 9.68 (s), 11.96 (s) 
-...J 
0"1 
TABLE V (Continued) 
Cpd. ArC-H Characteristic Bands Ar-OCH3 Miscellaneous Bands 
144 3.43 (s) OH, 2.80-3.10 (w) 8.93 (vs) 6.75 (vs), 8.18 (vs), ,__ 
keto C=O, 6.10 (vs) 9.60 (s), 12.05 (s), 
12.40 (s) 
106 ,__ 3.44 (s) NH, 3.04 (s) 8.99 (vs) 7.10 (w), 7.93 (m), 
9.68 (w), 12.18 (s), 
12.45 (s) 
107 3.42 (w) C=N, 6.25 (s) 8.96 (vs) 6.72 (vs), 7.92 (vs), 
~ 9.60 (w), 12.08 (s) 
155 3.45 (s) ester C=O, 5.80 (vs) 8.93 (vs) 6. 78 ( s), 7. 95 ( s) ' ,..._, 
keto C=O, 5.95 (vs) 9.65 (w), 12.07 (w) 
108 3.43 (w) NH, 3. 18 ( w) 8.94 (vs) 7.11 (s), 9.55 (s), ,,.._.,, 
keto C=O, 5.90 (vs) 12. 55 (w) 
125 3.44 (s) keto C=O, 6.01 (vs) 9.06 (s) 6.30 (vs), 7.99 (s), 
,,......- 11.85 (s), 12.45.(~) 
137 3.43 (w) NH, 2.80-3.10 (w) 9.02 (vs) 6.30 (vs), 7.48 (s), ,,......, 
Ar-N02, 6.20 (vs) 9.90 (w), 13.50 (w) 
143 3.40 (s) OH, 2.80-3.10 (w) 9.15 (s) 6.28 (vs), 7.55 (s), 
keto C=O, 6.07 (vs) 10.10 (s), 12.35 (s) 
98 3. 41 (vs) NH, 3.09 (vs) 9.18 (vs) 6.75 (vs), 7.80 (s), 











103 3.44 (s) 
150 3.42 (w) ......_, 
151 3.50 (s) 
--.._, 
152 3.45 (w) ---...... 
TABLE V (Continued) 
Characteristic Bands 
C=N, 6.30 (w) 
ester C=O, 5.79 (vs) 
keto C=O, 5.98 (vs) 
NH, 2.80-3.70 (s) 
C=O, 5. 80 (vs) 
ester C=O, 5.78 (vs) 
keto C=O, 6.01 (vs) 
NH2, 3.15 (s) 
OH, 3.60-3.90 (s) 
C=N, 6.10-6.50 (vs) 
OH, 2.85-3.05 (w) 
SH, 3.90 (w) 









6. 80 ( s), 6. 92 ( s) ' 
7.60 (w), 9.99 (s), 
12.40 (w) 
6.30 (vs), 7.85 (s), 
8.00 (s), 10.10 (w) 
6. 32 ( s), 9. 20 ( s) ' 
12.04 (w), 13.64 (w) 
6.97 (s), 8.22 (vs), 
8.69 (s), 11.86 (s) 
7.25 (s), 7.98 (s), 
12.78 (w), 13.18 (w) 
6.50 (s), 8.28 (w), 
12.20 (s) 
aValues given in wavelength (microns). The intensity of each peak is indicated as follows: (s) - strong, 
(vs) - very strong, (m)-medium, (w) - weak, (vw) - very weak. The spectra were all taken on KBr pellets, 
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TABLE VI 
NMR CHEMICAL SHIFTS AND COUPLING CONSTANTS OF PRODUCTS 
Cpd. Plate Solvent 
o" (values~ 
(p.p.m.) 
28 II DCC1 3 1.92-2.24 (p) ,,.._, 
JHH = 6.2 c.p.s . 
2.50-2.68 (t) 
JHH = 6.2 c.p.s. 
2.80-2.98 (t) 
JHH = 6.2 c.p.s. 
3.89, 3.87, 3.95 (3s) 
7. 39 ( s) 
139 ............ DCGl3 1.92-2.26 {p) IV 
JHH = 6.2 c.p.s. 
2.86-3.06 (t) 





















CH30J80.(e) NOCH3(d) ·o <c> 
CH 0 3 (a) 
( d )-----2:!3 0 ( b ) 
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JHH = 6.2 c.p.s. 
3.40-3.80 (s) 
Integr. Assignments 
2 CH2 (c} 
1 OH (d) 
------------------~---------------------------
VI DCCl3 
4.00, 4.14 (2s) 
7. 36 ( s) 
1. 96-2. 30 {p} 
JHH = 6 c.p.s. 
2.92-3.10 (t) 
JHH = 6 c.p.s. 
3.17-3.36 (t) 
JHH = 6 c.p.s. 
9 OCH3 (e) 
1 Ar-H (f) 
2 CH2 (a) 
2 CH2 (b) 





CH OJ$0(d) NNHCNH. (e) 
3 0 (b)2 
CHO 3 (a) 










4.19, 4.27 (4s) 
7.35 (s) 
1. 96-2. 24 (m) 
2.72-3.02 (m) 
3.98, 4.00, 4.11 (3s) 
7.62 (s) 




















NO (hV&-2 (g) 
3 · N02 
(b) CHOmNNH 0 
CHO 0 (e) ( f) 
( 
3 {a) 




TABLE VI (Continued) 
Plate Solvent 
x DCC1 3 
cS (values) 
(p.p.m.)a Integr. Assignments 
1. 88-2 .18 (m) 2 CH2 (a) 
----------------------------~-----------------
::~::::::_~~~~-------------~-------:~~-~~~----
3~88, 3.94, 3.97 (3s) 9 OCH3 (c) 
7.54 (s) 1 Ar-H (d) 
7.98-8.15 (d) 1 Ar-H (e} 
J ortho = 10 c.p.s. 
---------- ------------------------ .... - -----------
8.28-8.48 (d of d) 
J ortho = 10 c.p.s. 
J meta = 3 c:p.s. 
1 Ar-H (f) 
--- -- - -----.J~--------- --- ---- ----- - - - - - - --- -- --
9.10-9.17 (d) 1 Ar-H (g) 
J meta = 2 c.p.s. 





CH 0 {d) 0 (e) 
~~CHOH(f) ~{b) 
(c) H3 o (a) 
(a) (d) 97 



































OH ( f) 















( d} 3 
OCH3 (c} 
TABLE VI (Continued} 
Plate Solvent 
XVIII DCC1 3 
xx DCCl3 
o (values) 
{p.p.m.)a Integr. Assignments 








3.47-3.67 (d of d) 
JHH = 6 c.p.s. 















3.77 (s) 3 OCH3 (c) 
----------------------------------------------





( b) 0 ~
' 
8HO~. rN~H(e) ~(d) 
( c) H30 





( b) H30 







(p.p.m. }a Integr. Assignments 
7.38 (s) 1 Ar-H · (e} 
2.38-2.58 (m) 2 CH2 (a} 
----------------------------------------------. .. 











9.00-11.20 (bs) 1 NH, OH (e) 
DMSO-g6 2.38-2.82 (m) 2 CH2CH2 (a) 
3.75, 3.79, 4.03 (3s) 9 OCH3 (b) 
6.25-6.48 (s) 2 NH2 (c) 
----------------------------------------------








0 CH3 (a) 
OCH 3 (c) 




XXVIII DCC1 3 
8 (values) 
(p.p.m. )a Integr. Assignments 
10. 60-10. 94 1 OH (e) 
2.32"'.2.84 (m) 2 CH2CH2 (a) 
----------------------------------------------
3.76, 3.82, 3.91 (3s) 9 OCH3 (b) 
7.53 (s) 1 Ar-H (c) 
12.10-12.52 (d) 2 SH, OH (d) 
1.46 (s) 3 CH3 (a) 
1.80-3.10 (~) 4 CH 2CH2 {b) 
------------------------------------------~---·· 
3. 66 ( s) 


















TABLE VI (Continued) 
Cpd. Plate Solvent 
102 xxx DCC1 3 ,__ 
130 XXXII ,.._ DCCl3 
o (values) 
(p.p.m.)a Integr. Assignments 
1. 34 (s) 3 CH3 (a) 
----------------------------------------------
1. 58-2. 34 (m) 2 CH2 (b-) 
2.80-3.04 (m) 2 CH2 (c) 
----------------------------------------------
3.90 (s) 9 OCH3 (d) 




JHH = 6.5 c.p.s. 
2.39-2.60 (t) 
JHH = 6.5 c.p.s. 
1 NH {f) 
2 CH2 {a) 
2 CH2 (b) 
--------~-------------------------------------
2.94-3.16 (t) 2 CH2 (c) 
























7.14-7.38 (m) 3 Ar_;H (e) 
7.84-8.05 (m) 1 Ar-H (f) 
----------------------------------------------
8.30-9.30 (bs) 1 OH (g) 
2.10-2.40 (p) 2 CH2 (a) 
JHH = 6 c.p.s. 
----------------------------------------------
2.60-2.79 (t) 2 CH 2 (b} ····' · 
JHH·= 6 c.p.s. 
----------------------------------------------
3.17-3.35 (t) 2 CH2 (c) 





















JHH = 8 c.p.s. 
3.14-3.34 (t) 
JHH = 8 c.p.s. 
Integr. Assignments 
6 OCH3 (d) 
3 
1 Ar-H (e) 
2 Ar-H (f) 
2 CH2 (a) 








7.16 (s) 1 Ar-H (d) 






(b) ( e} 
__, 
TABLE VI (Continued) 
Plate Solvent 









14.38-14.70 (bs) 1 OH (g) 
-
2.82-3.04 (t) 2 CH2 (a) 
JHH = 7 c.p.s. 
----------------------------------------------. . 
3.18-3.40 (t) 2 CH2 (b) 
JHH = 7 c.p.s. 
3.98, 4.00, 4.03 (3s) 9 OCH3 {c) 
----------------------------------------------
7.16 (s) l Ar-H (d) 
7. 43 ( s) 1 CH {e) 
7.47 (s) 1 NH (f) 
7.81-7.95 (d) 1 Ar-H (g) 











(p. p.m. }a 
7.95-8.09 (d} 
J ortho = 9 c.p.s. 
2.82-3.06 (t} 
JHH = 8 c.p.s. 
3.25-3.55 (t} 
JHH = 8 c.p.s. 
3.89, 4.00, 4.03 (3s) 
7.11 (s) 
Integr. Assignments 
1 Ar-H (h} 
2 CH2 (a} 
2 CH2 (b} 
9 OCH3 (c} 
1 Ar-H (d} 
----------------------------·-----------------
7.69.,-7.80 (d} 1 Ar-H (e} 
J ortho = 9 c.p.s. 
----------------------------------------------
8.00-8.14 (d} 1 Ar-H (f) 






( b) H3~ 0 155 __. 
·ocH3( c) 

























7.ll(s} 1 Ar-H (e) 







{ c) H30 
(a) 
H C 
{ b) 3, 0 
Cpd. 
108 ,..._., 
TABLE VI (Continued) 
o (values} 
Plate Solvent (p.p.m.}a Integr. Assignments 







J ortho = 9 c.p.s. 
7.97-8.14 (d) 
J ortho = 9 c.p.s. 










. Ar-H (d} 
Ar-H (e) 










(c)~H 0 NNHJQ\-· .





TABLE VI (Continued) 
Plate Solvent 
XLVI DCC1 3 




J HH = .6 c . p . s . 
2.49-2.68 (t) 
JHH = 6 c.p.s. 
2.78-2.97 (t) 
JHH = 6 c.p.s. 
Integr. Assignments 
2 CH2 (a) 
2 CH2 (b) 
2 CH2 (c) 
----~-----------------------------------------
3~85, 3.90 (2s) 9 OCH3 (d) 
6. 52 ( s) 1 Ar-H (e) 
I. 83-2 .. 13 (m) 2 CH2 (a) 
----------------------------------------------
2.62-2.90 (m) 4 CH2 (b) 
3.93-3.99 (2s) 9 OCH3 (c) 
6.55 (s) 1 Ar-H (d) 
--------~------------------------------------- ~ (,.) 
Structure 
(c)E:H3o O (e) 
CH300ACHOH(f) 
CH o~(a) 










J nrtho = 9 c.p.s. 
8.27-8.44 (d of d) 
J ortho = 9 c.p.s. 
J meta = 3 c.p.s. 
9.12-9.19 (d) 




. 1 Ar-H (e) 
1 Ar-H (f) 
1 Ar-H (g) 
1 NH (h) 
2 Gl12 (a) 
-----------~----------------------------------
2.67-2.90 (m) 2 CH2 (b) 
----------------------------------------------. . 
3~87, 3.91, 3.96 (3s) 9 OCH3 (c) 
6.54 (s) 1 Ar-H (d) 




CH O,..~ .... OCH 









TABLE VI (Continued) 
Plate Solvent 
(values) 
(p. p.m. )a 
8.02-8.19 (d) 
Integr. Assignments 
1 CH (e) 
--------~-------------------------------------
14.3-14.7 (bs) 1 OH ( f) 
LII DCCl3 2.60-2.98 (m) 4 CH2CH2 (a) 
3.86, 4.01 (2s) 9 OCH3 (b) 
6.60 (s) 1 Ar-H (c) 
7.41 (s) 1 CH (d) 
8.78-9.02 (bs) 1 NH (e) 
LIV DCCl3 2. 59-3.JJ.6._{m) 4 CHzCH2 (a) 
3.89, 4.00 (2s) 9 OCH3 (b) 
6.63 (s) 1 Ar-H (c) 




(d )SH3o O CH3 (a) 
CH30~0CH3 (c] 
CH30 ( b) 
(e) 























3 CH3 (a) 
4 CH2CH2 (b) 
3 OCH3 (t) 
9 OCH3 (d) 
1 Ar-H (e) 
3 CH3 (a) 
4 CH2CH2 {b) 
3.88, ~.94 (2s) 9 OCH3 (c) 
----------------------------------------------
6.52 (s) 1 Ar-H (d) 
-----------------------------~----------------
















3.48-3.68 (d of d) 
JHH = 9 c.p.s. 




J meta= 3 c.p.s. 
6.76-6.92 (d of d) 
J ortho = 9 c.p.s. 
J meta = 3 c.p.s. 
Integr. Assignments 
4 CHfH2 (a) 
1 CH (b) 
3 OCH3 (c) 
3 OCH3 ( d) 
1 Ar-H (e) 
1 Ar-H (f) 
----------------------------------------------
7. 96-8. 10 ( d) 1 Ar-H (g) 









(p.p.m.)a Integr. Assignments 







7.85-8.00 (d of d) 
J ortho = 9 c.p.s. 
J meta= 3 c.p.s. 
10. 68 ( s) 
2 CH2 (b) 
3 OCH3 (c) 
2 NH2 (d) 
1 Ar-H (e) 
1 Ar-H ( f) 
1 Ar-H {g) 
1 OH (h) 
l..O 
co 
TABLE VI (Continued) 
8 (values) 
Structure Cpd. Plate Solvent (p.p.m.)a lntegr. Assignments 
152 LXIV DMSO-g6 2.32-2.59 (t) 2 CH2 (a) ---
OH(g) JHH = 8 c.p.s. 
2.64-2.90 (t) 2 CH2 (b) 
( c) CH30 
(f) 
JHH = 8 c.p.s. 
4.00 (s) 3 OCH3 (c) 
6.91 (s) 1 Ar-H (d) 
6.79-6.96 (d) 1 Ar-H (e) 
J ortho = 10 c.p.s. 
7.90-8.06 (d) 1 Ar-H. ( f) 
J ortho = 10 c.p.s. 
11.98-12.40 (bs) 2 OH, SH (g) 
aThe multiplicity of each peak is indicated as follows: singlet, s; broad singlet, bs; doublet, d; 











































































































aValues given in c units; in DCCl3. 
bFigures in parentheses denote number of methoxy groups via peak integration. Where not noted, the peak 





INTENSE IONS IN THE MASS SPECTRA OF PRODUCTSa 
Pressure Probe Source 
M+(% RI)b Cpd. (mm.} Temp. (0t) Temp. (0 c) 
28 2. 4 x 10-6 40 210 236(100) -
139 3.5 x 10-6 70 160 251( 100) ............ 
140 1 x 10-5 25 160 265(57) 
141 8 x 10-6 105 160 309(35) ,...._, 
[l/g(% RI) 
51(9), 77(18), 79(11), 
91(11), 107(10), 135(10), 
151(10), 165(23), 180(12), 
193(21), 194(11), 195(11), 
221(26)' 237(18) 
15(8), 33(17), 35(9), 
36(20)' 38(10)' 51(8)' 
77(12), 115(8), 116(8}, 
191(8), 236(28), 252(16) 
41(24), 43(23), 55(16), 
57(27), 70(16), 71(16), 
77(19), 113(15), 149(100), 
159(16), 167(47), 250(15) 
28(49), 29(37), 31(33), 
32(51)' 51(75)' 77(71)' 
91(38)' 151(55)' 193(32)' 
221(55), 236(100), 237(63), 
292(43) 
-0 w 
TABLE VIII (Continued) 
Pressure Probe Source 
M+(% RI)b Cpd. {mm.) Temp. (°C) Temp. (°C) ID/~(% RI) .. 
142 3.8 x 10-6 60 210 264(100) 77(9), 161(16), 189(18), --- 190(10), 204(33), 205(18), 
220(11), 221(19), 233(18), 
235(20), 236(19), 249(20), 
265(17) 
97 4 x 10-6 50 180 260(100) 15(8), 28(19), 31(12), - 51(5), 77(4), 131(10), 
159(7), 185(13), 202{7), 
217(6), 245(61), 246(10), 
261(18) 
99 4 x 10-6 50 220 261(100) 75(7), 130(5), 163(9), 
178(6), 184(8), 189(7), 
206{7), 218(8), 236(8), 
246(35), 247(5), 262(18) 
148 -5 60 250 294(27) 165(9), 180(5), 193{6), 2.5 x 10 -- 204(5), 219(5), 221(14), 
235(9), 236(100), 237(11), 
262(11), 263(5), 295(5) 
101 3.4 x 10-6 150 210 276(100) 115{3), 147(3), 175(4), 
192(3), 201(6), 205(5), 
218(3), 233(4), 261(57), 





TABLE VIII (Continued) 
Prtssu)e Probe Source M+(% RI)b Cpd. mm. Temp. (OC) Temp. (OC) m/g (% RI) 
102 1.2 x 10-5 90 150 290(41) 14(38), 18(21), 28(100), 
32(23), 40(23), 44(9), 
77(7), 115(8), 116(6), 
131(7), 181(6), 247(7), 
275(10)' 291(8) 
104 2 .8 x 10-6 155 240 303(100) 43(5), 152(6), 186(7), 
202(5), 228(4), 230(4), 
244(4), 272(8), 288(19), 
289(4), 302(23), 304(19) 
131 4.6 x 10-6 90 190 286(100) 63(19), 75(17), 101(16), -- 115(23), 126(16), 127(27), 
128(37), 129(25), 139(20), 
157(44), 172(20), 228(23), 
243(28), 271(24), 287(22) 
144 4 x 10-6 65 205 314(100) 64(5)' 138(5)' 151(5)' 
~ 164(5), 225(5), 254(10), 
271(14), 284(12), 285(7), 
286(11), 299(18}, 315(22) 
106 3 x 10-6 85 210 310(74) 77(13), 89(19), 126(17), ........... 152(17), 155(36), 181(25), 
223(23), 224(13}, 251(38}, 
267(61), 295(90), 296(20), 




TABLE VIII (Continued) 
Pressure Probe· Source 
M+(% RI)b Cpd. (nm.} Temp. (0 c} Temp. (OC) mfg(% Rl) 
107 3 x 10-6 110 250 311(100) 127(4}, 129(4), i82(6), ___, 
215(4), 230(7), 253(4), 
258(5), 268(9), 296(14), 
297(4)' 312(18) 
155 5.3 x 10-6 75 200 358( 100) 15(60), 28(34), 59(18), 
"'-' 115(24)~ 127(17), 141(21), 
149(18), 172(19), 215(20), 
230(27), 258(17), 298(49), 
299(27)' 359(24) 
108 2.8 x 10-6 150 260 340( 100) 139(6), 152(7), 153(7), 
~ 165(6), 211(5), 282(8), 
297(15), 325(18), 326(5), 
341(20) 
125 7 .4 x 10-6 50 160 236(96) 43(21), 77(18), 79(24), - 91(17), 150(25), 151(22), 
165(52), 193(28), 203(29), 
207(20), 208(18), 221(100), 
222(25), 237(17) 
143 5 x 10-6 50 210 264(100) 43(35), 51(13), 77(14), - 149(15), 161(15), 203(13), 
204(16), 221(15}, 235(27), 





TABLE VIII (Continued) 
Pressure Probe Source 
M+(% RI)b Cpd. {rrm. ) Temp. {°C) Temp. (°C) m/~(% RI) 
98 3 x 10-6 70 200 260(100) 51(29), 63(31), 65(18), 
75(22), 76(21), 77(43), 
78(18), 87(18), 115(20), 
130(26), 131(54), 159(31), 
185(28), 202(42), 245(20), 
261(19) 
100 6 x 10-6 80 200 261l l00) 15(15), 51(20), 63(15), - 77(21), 115(14), 131(13), 
191(13), 203(17), 208(15), 
218(22), 246(26), 262(52) 
154 3 x 10-6 60 260 308(25) 90(6), 121(5), 165(27), 
193(53), 194(8), 208(100), 
209(12), 221(19), 233(10), 
234(7), 248(34), 249(24), 
250(9), 261(7) 
.. 103 2.2 x 10-6 100 200 290(100} 69(13), 115(6), 131(5), 
~ 230(15), 231(42), 232(26), 
246(8), 247(9), 261(5), 
275(12), 291(20) 
150 -6 60 210 234(70) 43(9), 77(10), 91(10), 5.8 x 10 ,...._ 
103(10), 120(21), 148(100), 
149(10), 174(39), 175(18), 
176(36), 200(10}, 201(12), 
202(45), 203(19), 235(12) ..... 0 
-.....i 
TABLE VIIi (Continued) 
Pressure Probe Source 
Cpd. (mm.) Temp. (°C) Temp. (°C) 
151 2. 4 x 10-6 150 260 
152 2.8 x 10-6 165 260 -
aAll spectra were recorded at 70 eV (ionization potential}. 
bM+ symbolizes the molecular cation. 




18(34), 28(40), 31(19), 
43(29), 45(21), 115(17), 
227(25), 228(20), 242(57), 
243(64), 259(78), 261(17) 
43(10), 115(10), 130(8), 
199(12), 200(12), 214(18), 





RESULTS OF PEAK MATCHING ON SELECTED INTERMEDIATES AND PRODUCTS 
Cpd. Formula Fragmenta mle 
Possiblg 
Formula Calc'd 
C14H1605 M+ 264 ~ 264.0984 ,H, 
o' ? I c14H16°s I 264.0998 
CH3o~c,H 
M+-15 249 ~ 249.0749 CH30 
CH30 
142 I C13H13°s I 249.0762 --
M+-31 233 ~ 233.0800 
I C13H1304 I 233.0814 
C15H1806 M+ 294 ~ 294.1130 0 0 
II II 







TABLE IX (Continued) 
Possible 
Cpd. Formula Fragment a m/g Formulaa Calc 1 d Found 
148 M+-58 236 ~ 236.1022 --
~ 236 .1035 236.1014 
I c13H16°4 I 236.1048 
M+-73 221 ~ 221.0787 
~ 221.0800 221.0780 
I C12H1304 I 221. 0814 
C16H2006 
M+ 308 ~ 308.1233 
0 CH_ 
~ 308.1246 308.1258 OCH3 




TABLE IX (Continued) 
Cpd. Formula Fragmenta ml e 
153 M+-15 293 ---
C14H1605 
M+ 264 














I C12H13°4 I 
~ 


















TABLE IX (Continued) 
Fragmenta 
Possible 
Cpd. Formula ml~ Formulab Calc 1 d Found 
Cl6H2006 . M+ 308 ~ 308.1233 
CH30 . 0 CH3 ~ 308.1246 308.1252 
CH30~0CH3 I c16H20?6] 308.1260 




293 I c15H1106 I 293.1025 
~ 293.1038 293.1031 
~ 293.1052 
C13H18N203 M+ 250 ~ 250.1304 NNH2 250. 1311 
CH30~ I C13H18~2°3 I 250.1317 
CH 30 M+-15 235 ~ 235.1069 CH30 235.1075 




TABLE IX (Continued} 
Cpd. Formula Fragmenta m/g_ 
149 M+-31 219 --
C13H1404 M+ 234 
o- 0 






I en Hn N2o3 I 
~ 
I C13H1404 I 
~ 
~ 
I C12H1003 ] 
~ 

















TABLE IX (Continued) 
Fragment a 
Possible 
Cpd. Formula m/e Formulab Calc'd Found 
-
C14H16N2f>4 M+ 276 ~ 276.1097 
0 276.1099 
'I 
1 ·c14H16N204 I 276.1110 
M+-15 I C13H13N204 I 261 261. 0875 
261.0891 
~ 261. 0889 IOI - --
C15Hl8N204 M+ 290 ~ 29.0.1253 290.1253 
H3~ _O I c15HiaN204 I 290.1266 
M+-15 275 I C14H15N204 I 275.1032 275.1036 
CH30'Y'OCH3 ~ 275.1045 
CH30 
M+-59 ~ 103 231 231.1008 - 231.1025 
I c1~H1503 I 231.1021 
aM+ symbolizes the molecular action. ..... 
bConfi rmed fragment I 
..... 
I, unobserved fragment~- -I=> 
115 
vacuum via a spinning band distillation apparatus led to alkene forma-
·tion to yield m-methoxystyrene and subsequent polymerization. None of 
the bromide!.§ was isolated in a pure form .. Aft~r repeating this 
general procedure several times without success, an alternate method was 
tried (Scheme 22). It had been reported that the purity of the N-
158 --
Scheme 22 
CH 0 3 
157 --
bromosuccinimide (NBS) was critical to the preparation of bromo-
methylarenes. 33 However, even after purification of NBS, only the 
bromoarene derivative (4-bromo-3~methylanisole) could be obtained from 
treatment of m-methylanisole with NBS. 95 Thus an alternate scheme was 
proposed (Scheme 23). 
Stork had recorded134 the preparation of lQ! from the Reformatsky 
reaction of 6-methoxy-1-tetralone (ill) and methyl y-bromocrotonate. 
Reduction of expected ester _IB with hydrogen in the presence of Raney 
nickel at room temperature (followed by hydrolysis) gave the partially 
reduced ac;:id !§.§ which he successfully cycl ized to the phenanthrone 

















I) H2 (Ni} 












then easily be converted to 167 with lithium metal in liquid ammonia.32 ,,...._,, 
Vi 11 ani and co-workers 148 studied the hydrogenation step in this 
sequence and found that only in the presence of a small amount of acetic 
acid and freshly prepared Raney nickel (W-2) could a good yield of ~ 
be achieved. Following strict adherence to the described quantity of 
reagents and reaction conditions, attempts to prepare J.Q§_ from pure !.§.! 
were initiated. In three separate trials only the completely saturated 
acid 168 was isolated. The Raney nickel was freshly prepared each time 
168 ,......._,, 
following the method of Mozingo. 102 One explanation of the failure to 
obtain 165 could be the difference in activity of the nickel catalyst. --
Thus, attempts to prepare 166 or 167 were abandoned. 
. - --
In view of the importance of water solubility in biological activ-
ity of many compounds, efforts were made to cleave the methoxy groups to 
give hydroxy functions. Many methods are known for complete or partial 
demethylation of polymethyl aryl ethers. A few representative examples 
are: the use of 20% HCl for partial demethylation, 133 hydrogen bromide-
acetic acid cleavage of methoxytetralones, 70 demethylation of khellin by 
magnesium iodide, 123 demethylation of the tetramethyl ether with 
aluminum chloride-sodium chloride to yield spinochrome N, 130 cleavage of 
alkyl ethers with lithium iodide, 63 demethylation of aryl methyl ethers 
by boron tribromide, 41 ,97 use of 48% hydrogen bromide in the cleavage of 
dimethoxyhetero compounds, 64 and the use of pyridine hydrochloride in 
methoxy cleavage of several naturally occurring compounds. 39 ,54 
When 48% hydrogen bromide was used in the trial preparation of 
3,4-dihydro-1(2H)-naphthalenone-5,6,7-triol (169), only a tar formed. - ,...__, 
Heating 5,6,7-trimethoxy-1-tetralone (28) with freshly fused pyridine -
hydrochloride for two hours gave a slightly impure 3,4-dihydro-1(2.ti)-
118 
naphthalenone-5,6,7-triol (169). ---- Treatment of the 6,7,8-trimethoxy-1-
tetralone (125) under the same conditions did give pure 170 as indicated --- ,......._ 
0 HOM HOI$0 HO HO 
HO HO 
HO HO HO 
169 170 
HO HO --- --- 171 172 ----- --
by e 1ementa1 and spectral analyses. However, treatment of pyrazole n 
with freshly fused pyridine hydrochloride resulted in a partially 
demethylated product, as evidenced by the NMR data, which showed a 
singlet {o 3.78) in the methoxy region. Possibly a longer reaction time 
was needed in this system for cleavage of all the methoxy groups but 
this was not attempted. Attempts to obtain the trihydroxy derivative of 
isoxazole ~ gave only a tar residue from which no product could be 
isolated. 
Microbial and Tissue Culture 
Screening Techniques 
The initial screens chosen, while limited in scope, were to 
determine activity of a compound against growth of bacterial or tumor 
cells. Bacillus subtilis W23 (a prototrophic strain) and Pseudomonas 
119 
fluorescens NND were chosen for the microbial screening. Bacillus 
subtilis is an aerobic, gram-positive rod which grows' in a minimal 
medium, using glucose as the sole source of carbon and energy. 
Pseudomonas fluorescens is a gram-negative rod. It also grows in a 
minimal medium. The Pseudomonads are resistant to many drugs, including 
actinomycin D, and are the cause of many deaths in cancer patients. 18 ,121 
The inhibition of growth of bacteria is a general screen and could show 
inhibitory effects of the compound but without providing evidence for 
the mechanism of inhibition. These tests have the advantage of ease of 
performance and can be run utilizing a suspension of the test compound. 
Use of the suspension permits the screening of water-insoluble compounds 
but obscures possible advantages of good aqueous solubility which could 
reduce the dosage needed. Bacillus subtilis and P. fluorescens were 
maintained on 0.5% glucose salts minimal medium. 16 A weighed sample 
(~ 1 mg.) of compound to be tested was suspended in 0.5 ml. of dimethyl 
sulfoxide (DMSO) and diluted with sterile water (4.5 ml.). Growth 
experiments were performed in tubes (12 mm x 150 mm) containing 5.0 ml. 
of glucose salts medium, 0.5 ml. of DMSO solution and 0.2 ml. of cell 
inoculum to give a final volume of 5.7 ml., which turned out to be 91 
µg/ml (final compound concentration). The cultures were incubated for 
12 to 14 hr. at 37° with constant shaking and cell growth was .measured 
by following the change in absorbance at 540 mm in a Coleman Junior II 
Spectrophotometer {18-nm light path). 31 ,68 Optical density generally 
started at 0.04 and was read at 1 hr. intervals. Inhibition was shown 
by little or no change i.n optical density over a period of 12 to 14 hr. 
All samples were run in either duplicate or triplicate with the same 
number of controls so either inhibition or activation of growth could be 
120 
observed. The results of the microbial screens are given in Table X. 
Those compounds showing some activity in the microbial screens were 
evaluated on their ability to inhibit the plating efficiency of the 
human tumor cell line - KB. The latter is an established cell line 
derived fr6m human tumors of the nasopharynx. Plating efficiency 
encompasses the ability of the cells to attach to a surface and com-
plete all cell cycle functions responsible for colony formation. This 
procedure requires small volumes of test compound and it is very repeat-
able and relatively simple to run. All tissue culture ptocedures suffer 
from the necessity of requiring test compounds in solution, and the lack 
of the presence of such variables as excretion processes, filtration 
processes, hormone interaction, etc., that miqht be confronted by a 
compound in the whole animal. 
The KB cells, originally obtained from Dr. Vernon Scott •(University 
of Oklahoma Medical School}, were grown at 37° using medium 199 supple-
mented with 10% calf serum. A known weight of the test compound was 
dissolved in 0.05 ml. DMSO and 2.0 ml. of water was added. To 10 mm x 
35 mm Falcon plastic tissue culture dishes was added 1.5 ml. of the 
aqueous solution containing the test compound (of known cone.} and 
1.5 ml. of 2x medium containing the KB cells for a total of 3.0 ml. of 
lx medium (growth medium of lx is the ideal nutrient level for these 
cells} containing approximately 103 cells/plate. The cultures were 
incubated in a co2 gas phase incubator (5% co2} at 37° for 7 days. 
After removal of the medium, the plates were washed with Hank's salt 
solution and the cells stained with 0.5% aqueous crystal violet, rinsed, 
and dried. The colonies were counted microscopically and the relative 
plating efficiency calculated using the control value of 100%. Samples 
121 
TABLE X 
ACTIVITY OF PRODUCTS IN MICROBIAL TESTS 
Compound Name Cpd. 
Oxime of 28 139 ,...._., ---
Methoxime of 28 140 ,,....._, ,__. 
Thiosemicarbazone of 28 141 ,,,..._, ,,...._,, 
2,4-Dinitrophenylhydrazone 136 
of 28 ---,,....._, 
4,5-Dihydro-6,7,8-trimethoxy- 97 
l!i_-benz [g] i ndazo 1 e 
,......, 
4,5-Dihydro-6,7,8-trimethoxy- 99 




benz [g] indazol-3-one -
4,5-Dihydro-7,8,9-trimethoxy- 98 

















ainhibition shown by+; no inhibition, 
inhibition by ~· 





+ - (4 hr. lag) 
+ 
not tested not tested 
not tested not tested 
+ 
slight inhibition or delayed 
122 
were always run in either duplicate or triplicate. Results of the tis-
sue culture screen are given in Table XI. Plots showing the effect of 
concentration of the test compound and percent plating efficiency are 
shown in Figure 7. It must be recalled that as the percent plating 
efficiency decreases, the inhibition for the formation of colonies, and 
hence for growth, increases. 
Calculations of Distances Between 
Heteroatoms of Selected. 
Products 
Since models were not used in determining the distance between 
heteroatoms, several assumptions had to be made to obtain reasonable 
bond lengths and angles which could be used in the calculations of 0-N-O 
distances. First, each molecule was considered planar with respect to 
the aromatic region and conjugated double bonds. Also, the internal 
bond angles of the aromatic rings were considered to be 120°. 135 Simple 
0 . 
C-C bond lengths were assumed to be 1.54 A; simple C=C bond lengths were 
considered to be 1.34 R; and the single bond between two double bonds, 
C=C-C=C, was taken to be 1. 49 ~. 135 The crysta 1 data obtained from 
DL-iso-crystopleurine methiodide {172) reported by Fridrichsons and --- ,,....._ 
Mathieson53 gave approximate distances between the aromatic C and the 
I 
172 ---
C-0 1.36 + 0.02 ~ 
0 
ArC=C 1.39 + 0.02 A 
TABLE XI 
PERCENT PLATING EFFICIENCY OF KB CELLS VERSUS 
CONCENTRATION OF PYRAZOLES AND 111 _.___ 




























































% Pl. Eff. 
56 
0 
methoxy 0 (C-0) was taken to be 1.36 A; the C=C bond distances in the 
0 
aromatic portion ·of the molecule were averaged to b~ 1.39 A. 
In the pyrazole systems, pertinent data were obtained from ><-ray 
diffraction data reported by Gour and Rasmussen38 on pyrazole (!U.). 
0 





1.34 + 0. 02 A 
0 
1.34 + 0. 02 A 
L N-N(H)-C 112.4 + 0.06° 
L C-C-N(H) 106.5 + 0.06° 
bond distance, 1.34 ~; L N-N(H)-C, 112.4°; L C-C-N(H), 106.5°. Later 
the bond lengths and angles for indazole (174) were evaluated by Escande - 0 
C-NH 1.35 + 0.01 A 
@) 0 N-N 1. 38 + 0. 01 A 
H L N-N(H)-C 110 + 1.00 
174 
LC-C-N(H) 107 .4 + 1.0° -
100 
Cone. of Cpd. 
( ..ug./m I.) 
50 
50 100 
% Plating Efficiency 
Inhibition Increases 
106 
Figure 7. Concentration of Compound vs. Percent Plating 
Efficiency on KB Cells 
125 
and Lapasset,46 but recalculation using the values for indazole made 
little difference in the systems reported here. 
126 
4-Amino-3-isoxazolidine (175) 143 was used as a model for obtaining --
data for the isoxazole systems. It was recognized that this was not a 
OLlNH2 0 N-0 1.37 + 0.02 A 
HN \ 0 
'0 C-0 1.36 + 0.02 A 
175 L C-0-N 109 + 1° 
~
perfect model, yet due the scarcity of related models this seemed to be 
the most efficient. From 175, the N-0 distance is approximated to be -0 0 
1.37 A, C-0 distance~ 1.36 A, and the L C-0-N ~ 109°. 
Thiophene (176) 2 was used as a model in estimating the C-S bond ,..__ 
0 
C-S 1.72 + 0.02 A 
176 
Lc-s-c 91.3 + 0.2° 
--
0 
length to be 1.72 A and the C-S-C angle to be 91.3° in the thiazole 11!· 
Computations were done by a triangulation between points of 
estimated distances and making use of simple trigonometric functions. A 
representative example of the computations is shown in Figure 8 for 3,4-
di hydro-6, 7-d i methoxy-lH-benz [ g] i ndazo le (!@). Similar calculations 
97 98 --
were made on pyrazoles 2Z. and~· In the case of 2l_, triangles ~KCE in 
177 (C denotes the center of the aromatic ring), ~KEF in 178, and ~KFG -- ,,.....__ 
0 
in 179 were used to determine heteroatom distances of KF = 6.17 A and ---
Assume that L\BCH and ~ACI are equilateral triangles 
with internal angles of 60°: 
0 
BC = BH = HC = 1.39 A 
0 
AB = HI = 1.36 A 
0 
AC = IC = AI = AB + BC = 1.36 + 1.39 = 2.75 A 
Assume A and E are colinear 
0 
AE =AC+ CD+ DE = 2.75 + 1.39 + 1.49 = 5.63 A 
Consider MEF 
L JEF = 106.5°. LAEJ = 120° 
0 
EF = 1. 34 A 
L AEF = 360° - L AEJ - L JEF 
L AEF = 360° - 120° - 106.5° = 133.50 
AF2 = AE 2 + EF2 - (cos L AEF)(2)(AE)(EF) 
AF2 = (5.63) 2 + (1.34) 2 - (cos 133.5°)(2)(5.63)(1.34) 
0 
AF = 6.63 A 
2 2 2 
cos LAFE = (EF) + (AFi - (AE) 
2(EF) AF) 




cos LAFE = (1.34)2 + (6.63)2 - (5.63)2 
2(1.34)(6.63) 
LAFE = 38.0° 
Consider t:.AFG 
0 
L EFG = 112.8°, FG = 1.34 A 
L AFG =LAFE +L EFG = 380 + 112.80 = 150.80 
AG 2 = AF 2 + FG2 - (cos L AFG)(2)(AF)(FG) 
AG 2 = (6.63) 2 + (1.34) 2 - (cos 150.8°)(2)(6.63)(1.34) 
AG= 7.81 ~ 
Consider t:.CEI 
0 
CE = CD + DE = 1.39 + 1.49 = 2.88 A 
L ECI = 120° 
EI 2 = (CI) 2 + (CE) 2 - (cos L ECI)(2)(CI)(CE) 
EI 2 = (2.75) 2 + (2.88) 2 - (cos 120°)(2)(2.75)(2.88) 
EI = 4.88 ~ 
cos L CEI = (CE}2 + (CI)2 - (EI)2 
2(CE)(CI) 
Figure 8 (Continued) 
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L FEI = L AEF - L CEI = 133.5° - 29.2~ = 104.3° 
FI 2 = (EF) 2 + (EI) 2 - (cos L FEI)(2)(EF)(EI) 
FI 2 = (1.34) 2 + (4.88) 2 - (cos 104.3°)(2)(1.34)(4.88) 
FI = 5.37 E 
cos L EFI = 
cos L EFI = 
(EF) 2 + (Fir- (EI) 2 
2(EF) FI) 
(1.34) 2 + (5.37) 2 ~ (4.88) 2 
2(1.34)(5.37) 
LEFI = 61.6° 
Consider 6FGI 
LGFI = LEFG + LEFI = 112.8° + 61.6° = 174.0° 
IG 2 = (GF) 2 + (FI) 2 - (cos L GF1)(2)(GF)(FI) 
IG2 = (1.34) 2 + (5.37) 2 - (cos 174.4°)(2)(1.34)(5.37) 
0 
IG = 6.71 A 
Figure 8 (Continued) 
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0 
KG = 7.05 A. Previous calculations on 16~ were used for heteroatom ,.....__ 
0 0 0 0 
distances of AF = 6.63 A, AG = 7~81 A, IF = 5.37 A, and IG = 6.71 A. 
I I 




Triangles b.LEC in 180, b.LEF in 181, and b.LFG in 182 were used for 
,..._ ---
A A 
I I I 
180 181 182 -- --
the heteroatom distances LF and LG in pyrazole ~.' The values found 
0 0 
were: LF = 2.80 A and LG= 4.13 A. Values for AF, AG, FI, and GI were 
assumed to be identical to those calculated for 109. Distances KI and -
AL as shown in {183) are considered identical; AL was calculated using -
triangle DAIL in ll!,1 by assuming angle AIL to be 120°. Thus the 
183 184 - ---
AL 2 = (AI) 2 + (LI) 2 (cos L AIL)(2)(AI)(LI) 
AL 2 = {2.75) 2 + (2.75) 2 - (cos 120°)(2)(2.75)(2.75) 
0 
AL = 4.76 A 
distance between the most distant methoxy groups in all of the 
0 
trimethoxy systems prepared was calculated to be 4.76 A. Identical 
types of computations were made for the isoxazoles 22. and !QQ, using 
b 0 . 
bond lengths EF = 1.36 A and FG = 1.37 A and bond angle L EFG = 
131 
109°. 143 Tabulations of the resulting distances are given in Table XII, 
with the distances calculated on the 11 model 11 pyrazoles 109, 97, and 98. 
,..._,. ,..._, ,....,J 
Table XIV contains the 0-N-O angle value~ calculated using triangles 
t.KAF in 185, t.KAG in 186, t.AFI in 187, t.AGI in 188, t.Fil in 189, and ,.._,,,,,. ,..,,.,_, ,....._ ,,__ ~ 
t.GIL in 190 in the simple trigonometric function cos ABC = --
AB 2 + BC 2 - AC 2 













Steps used in calculating heteroatom distances in the hetero-
steroids 106 and 107 are shown in Figure 9 for the pyrazole 106. The --- --
identical sequence was used for the isoxazole 107, the only difference --
being the insertion of appropriate bond lengths and angles for 0-N and 
C-0 bonds (see discussion of !Z§.1on page 126). Tabulation of the final 
results is shown in Table XIII. Calculation of 0-N-O angles was 
Cpd. R R' Ru 
109 H CH30 CH30 ---
97 CH30 CH30 CH30 
98 H CH30 CH30 -
203 H CH30 CH30 
99 CH 30 CH30 CH30 
100 H CH30 CH30 
TABLE XII 
0 




R-R 11 or 
R' II x R1-R 11 R'-R11' R-X R'-X R11 -X R111 -X 
H N 2.75 - 6.17 6.63 - -
H N 2.75 4.76 6.17 6.63 5.37 -
CH30 N 2.75 4.76 - 6.63 5.37 2.80 
H 0 2.75 - 6.18 6.64 - -
H 0 2.75 4.76 6.18 6.64 5.39 -



















Assume planarity of all atoms signified. 
Consider MOE. 
0 
AD =AC +CD= 2.75 + 2(1.39) = 5.53 A 
DE = 1.39 ~ (C=C) 
LADE = 1200 
AE 2 = (AD) 2 + (DE) 2 _,(cos L ADE}(2)(AD)(DE) 
AE 2 = (5.53) 2 + (1.39) 2 - (cos 120°)(2)(5.53)(1.39) 
0 
AE = 6.37 A 
cos LAED = (DE)2 + (AE)2 - (AD)2 . · 2(DE)(AE) 
cos L AED - (1.39)2 + (6.37)2 - (5.53)2 
- 2(1.39)(6.37) 
LAED = 49.1° 
Consider llAEF 
L AEF = L AED + LDEF = 49.1° + 120° = 169° 
AF2 = (AE) 2 + (EF) 2 - (cos LAEF)(2)(AE)(EF) 
AF 2 = (6.37) 2 + (1.39) 2 - (cos 169°)(2)(6.37)(1.39) 
Figure 9. Calculation of Heteroatom Distances in 
10,ll-Dihydro-6,7,8-trimethoxy-3H-
phenan thro[ 1, 2-~] pyrazo 1 e ( !Q§) -
133 
0 
AF= 7.84 A 
cos LAFE = (AF)2 + (EFt2 - (AE)2 
2(AF)( F} 
cos LAFE= (7.84)2 + (1.39)2 - (6.37)2 
2 (7. 84)(1. 39) 




LEFG = 133.5°, FG = 1.34 A 
L AFG = LAFE + L EFG = 8. 5o + 133. 50 = 142° 
AG 2 = (AF) 2 + (FG) 2 - (cos L AFG)(2)(AF)(FG) 
AG 2 = (7.84) 2 + (1.34) 2 - (cos 142°)(2)(7.84)(1.34) 
AG = 8.62 ~ 
cos L AGF = (AG)2 + (FG~2 - (AF)2 
2(AG) FG) 
cos L AGF = ( 8. 62) 2 + ( 1. 34 )2 - ( 7. 84) 2 
2(8. 62)( 1. 34) 




L FGH = 112. 8°, GH = 1. 34 A 
Figure 9 (Continued) 
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LAGH = LAGF + L FGH = 50.7° + 112.ao = 163.5° 
AH 2 = (AG) 2 + (GH) 2 - (cos LAGH)(2)(AGj(GH) 
AH 2 = (8.62) 2 + (1.34) 2 - (cos 163.5°)(2)(8.62)(1.34) 
0 




KJ = 1.36 ~' KJF = 120° 
0 
JF = JE + EF = 3(1.39) + 1.49 = 5.66 A 
KF2 = (KJ) 2 + (JF) 2 - (cos lKJF)(2){KJ)(JF) 
KF 2 = (1.36) 2 + (5.66) 2 - (cos 120°)(2)(1.36)(5.66) 
KF = 6.45 ~ 
cos L KFJ = (JF)2 + (KFr - (KJ)2 
2(JF) KF) 
cos L KFJ = (5.66)22C5~~61Z~~4S)(l.36)2 




L KFG = L EFG - L JFK= 133.5° - 10.5° = 123° 
0 
FG = 1. 34 A 
Figure 9 (Continued) 
135 
KG 2 = (KF) 2 + (FG) 2 - (cos LKFG)(2)(KF)(FG) 
KG 2 = (6.45) 2 + (1.34) 2 - (cos 123°)(2)(6.45)(1.34) 
0 
KG= 7.27 A 
LKGF = (KG) 2 + (FGi 2 - (KF) 2 cos 2(KG) FG) 
cos L KGF = ( 7. 27) 2 + ( 1. 34) 2 - ( 6. 45) 2 
2(7 .27)(1.34) 




L KGH = L FGH = L KGF = 112.8° + 480 = 160.80 
KH 2 = (KG) 2 + (GH) 2 - (cos L KGH)(2)(KG)(GH) 
KH 2 = (7.27) 2 + (1.34) 2 - (cos 160.8°)(2)(7.27)(1.34) 
KH = 8.55 ~ 
Consider tiLCD 
0 0 
LLCD = 120°, LC= 2.75 A, CD= 2(1.39) = 2.88 A 
LD 2 = {LC) 2 + (CD) 2 - {cos LLCD)(2)(LC)(CD) 
LD 2 = (2.75) 2 + (2.88) 2 - (cos 120°)(2)(2.75)(2.88) 
0 
LD = 4.82 A 
Figyre 9 (Continued) 
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cos L LDC = (LD)2 + (CD( - (LC)2 
2(LD) CD) 
cos LLDC = (4.82)2 + (2.88)2 - (2.75)2 
2(4.82)(2.88) . 
LLDC = 29.6° 
Consider b.LDE 
0 
L COE = 120°, DE = 1. 39 A 
L LOE = L LDC + L COE = 29. 6° + 120° = 149. 6° 
LE 2 = (LD) 2 + (DE)2 - (cos LLDE)(2)(LD)(DE) 
LE 2 = (4.82) 2 + (1.39) 2 - (cos 149.6°)(2)(4.82)(1.39) 
0 
LE = 6.06 A 
cos L LED = (DE)2 + (LEt - (LD)2 
2(DE) LE) 
cos L LED = ( 1. 39) 2 + ( 6. 06 r -( 4. 82) 2 
2 ( 1. 39 )( . 06) 
L LED = 23. 7 
Consider b.LEF 
LLEF = LLED + LDEF = 23.7° + 120° = 143.i0 
LF2 = (LE)2 + (EF) 2 - (cos L LEF)(2)(LE)(EF) 
Figure 9 (Continued) 
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LF 2 = (6.06) 2 + (1.49) 2 - (cos 143.1°)(2)(6.06)(1.49) 2 
0 
LF = 7.31 A 
LEFL = (EF) 2 + (LF~ 2 - (LE) 2 cos 2(EF) LF) 
cos LEFL = (1.49 2 + (7.31 2 - (6.06)2 
2 1.49 7.31 
L EFL = 29. 3° 
K 
Consider ilLFG 
L LFG = L EFL + L EFG = 29. 3° + 133. 5° = 162. s0 
LG 2 = (LF) 2 + (FG) 2 - (cos L LFG)(2)(LF)(FG) 
LG 2 = (7.31) 2 + (1.34) 2 - (cos 162.8°)(2)(7.31)(1.34) 
LG = 8.60 ~ 
cos L LGF = (LG)2 + (FGt2 - (LF)2 
2(LG) FG) 
cos LLGF = (8.60)2 + (1.34)2 - (7.31)2 
2(8.60) (1.34) 
LLGF = 14.4° 
K 
Consider ilLGH 
LLGH = L LGF + LLGH = 14.4° + 112.8° = 127.2° 
Figure 9 (Continued) 
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LH 2 = (LG) 2 + (GH) 2 - (cos L LGH) (2) (LG) (GH) 
LH 2 = (8.60) 2 + (1.34) 2 - (cos 127.2°)(2)(8.60)(1.34) 
0 
LH = 9.47 A 
Figure 9 (Continued) 
achieved by the same process used on the 11 model 11 compounds employing 
triangles ~LAG in 191, ~LAH in 192, ~GK in 193, and ~HK in 194. ,,,.....,_,,, ,,......,_ ,.._,,. ,,...._, 









Because of the bi,ological activity of 2-amino-4,5-dihydro-7 ,8-
dimethoxynaphtho[l,2-g] thiazole (.!1.!) 64 exhibited in both the microbial 
11 I 
Cpd. R R' 
110 CH30 CH30 
106 CH30 CH30 
204 CH30 CH30 -
107 CH30 CH30 
TABLE XIII 
0 
CALCULATED HETEROATOM DISTANCES (A) IN PYRAZOLOSTEROIDS 
R 
R' 
Ru x R1 -R 11 R-R 11 R-X R1 -X R11 -X 
H N 2.75 - 8.60 8.62 -
CH30 N 2.75 4.76 8.60 8.62 7.27 
H 0 2.75 - 8.61 8.76 -
CH30 0 2.75 4. 76 8.61 8. 76 7.27 
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and tissue culture screens, the heteroatomic distances of 111 were also --
computed. Calculations similar to the "model" pyrazole 109.were made -
using the following triangulations: 6AEF in 195, 6AFG in 196, 6AGM in 
__... ---
A A 
I I I 
195 196 197 -- - ~
I $\ s s 
E ,./G-M I 'G-M I );_M E ~ E...,F,+J ,' I .... F '.f I / /,. , , , , 
I / ~ " , 
A / A ~ A ", // /.. /, "'" I/ "" // I I" t'"' 
198 199 200 -- -- ___,... 
201 202 - -
ill' 6IEF in~' 6IFG in ill' and &IGM in lQQ_. Triangles 6AFI in~ 
and6AMI in 202 were· used for determining 0-N-O angles. Results of -
these calculations are shown in Table XV. 
Correlation of Structure to 
Biological Activity 
There has always been considerable interest in establishing the 
TABLE XV 
CALCULATED HETEROATOM DISTANCES AND ANGLES IN 2-AMIN0-4,5-DIHYDR0-

































relationship of chemical structure to biological activity. Not only is 
an interpretation of this type fundamental to the understanding of the 
function of drugs, but also it is basic to the rational desiqn of more 
effective analogs. 
Pyrazoles were selected for this correlation due to the activity 
they exhibited in the growth studies of~· subtilis and the consequent 
tissue culture screening. Since the heterocyclic ring is identical in 
all cases, it is not unreasonable to assume that either the number 
and/or orientation of methoxy groups or the heteroatomic distances 
between the methoxy oxygen atoms and the pyrazole nitrogen atoms might 
be significant in the exhibited biological activity. Therefore, a study 
of such parameters was undertaken. 
Table XVI gives a comparison of the percent of plating efficiency 
exhibited to the number and position of methoxy groups in "model" 
systems and the pyrazolosteroids. Because of the relatively large 
effort devoted to synthesis and the number of compounds purified (and 
analyzed), caution is required in making comparison of the number of 
methoxy groups present and the biological activity expressed at a given 
concentration of compound. However, with the data available, no direct 
correlation is apparent between the number of methoxy groups and the 
percent plating efficiency of KB cells. Obviously, for statistical 
significance one should include many more compounds and also the 
monomethoxy and tetramethoxy derivatives. 
It is interesting that the dimethoxy pyrazolosteroid 110 did not -
exhibit any inhibitory effects on plating efficiency up to 150 µg./ml. 
The trimethoxy-substituted pyrazolosteroid 106 exhibited little effect ___.. 






COMPARISON OF METHOXY ORIENTATION IN 11 MODEL11. SYSTEMS AND PYRAZOLOSTEROIDS 
AND PERCENT PLATING EFFICIENCY AT DIFFERENT CONCENTRATIONS 
R 
R' 
R R' Ru R' II 25 µg./ml. 
% Plating Efficienc~ 
50 µg./ml. 
H CH30 CH30 H 65 31 
CH30 CH30 CH30 H 100 91 








Cpd. R RI Ru 
110 CH30 CH30 H ---
106 CH30 CH30 CH30 
~ 







% Plating Efficienc~ 







observed at 150 µg./ml. (15% plating efficiency, 85% inhibition). 
However, all of the 11 model 11 compounds were totally inhibitory at 150 
µg./ml. This might indicate that size itself is important. Solubility 
differences might also be significant here as the 11 model 11 compounds are 
more water-soluble. 
Comparisons of the ratios of heteroatomic distances (2:_ 1) distinct 
for each compound and the percent plating efficiency are shown in Table 
XVII. For example, 4,5-dihydro-6,7,8-trimethoxy-1!!_-benz[g]indazole (fil) 
contains three methoxy groups, yet only ratios ~~=~~ and ~::~: are 
distinct because the ratios ~:=~~ and ~:=~~ are also formed in 4,5-
dihydro-7,8-dimethoxy-lH-benz[~Jindazole (~)and 4,5-dihydro-7,8,9-
Q3-Nl Q3-N2 
trimethoxy-lH-benz[~]indazole (~). Ratios 02 _N 1 and 02 _N 2 are con-
sidered unique for 109 because no other possibilities exist. Although -
111 is not a pyrazole, data for it are also included because of its -
somewhat related structure and biological activity. Only 0-N distances 
are considered for this compound since none of the pyrazoles contain 
sulfur. 
A graphical presentation of these data is given in Figure 10, where 
oA-N the 08_N ratios calculated are plotted against the precent plating 
efficiency of KB cells at a test compound concentration of 50 µg./ml. 
For three compounds (97, 98, and 109) maximum and minimum heteroatom - - -
distances (0 1-N 1 , 02 -N 1 , 03-N 1 , 03-N 1 ) were calculated using standard 
deviation values from the x-ray data selected for bond lengths in the 
models used. Maximum and minimum ratios calculated from these data are 
represented by the three bar lines in Figure 10. There is no obvious 
reason to assume that the 1 imi ts of !the ranges for the· remaining points 
would deviate significantly from wh~t we ~~~e found for 'the ranges of 
TABLE XVII 
A 
COMPARISON OF OB-N RATIOS OF PYRAZOLES AND 111 AND PLATING EFFICIENCY 
0 -N __, 
Cpd. Reference Cpd. Ratio Calc'd 
97 
01-N1 
02 -NI = .931 
01-N2 
02-N2 = .903 97 _., 
03-N1 
02-N i = .810 109 -
109 
03-N2 
02-N2 = • 859 
98 
Oi+-N 1 
Q3-N1 = .521 
98 Oi+-N
2 
03-N2 = .615 
% Pl. Eff. at 














.. . ·-- ---
02~ 106 --(03) 
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the three points chosen. 
Calculation of the correlation coefficient (r) using the equation 
given [where X and V represent the mean values and Xi (ratio) and Yi 
r = ~{X; - X)(Y; - Y) 
j ~(Xi - X) 2 ~ (Yi - Y) 2 
(plating efficiency) represent the individual values], indicates that a 
probable correlation exists. Consideration of only the ~~=~~ points 
(n = 6) gave r = .914; consideration of only the o:-N: points (n = 6) 
0 -N 
gave r = .855; consideration of all points (n = 12) gave r = .875. 
Confidence li~its107 (n = 6, r ~ .815, 95%; n = 6, r ~ .920, 99%; n = 12, 
r ~ .575, 95%; n = 12, r ~ .710, 99%) indicates a better than 95% 
probability of correlation. Although the sample size is small, there 
does seem to be a general trend in that as o:-N approaches 1, inhibition 
0 -N . A 
decreases (plating efficiency approaches 100%) and the more OB-N deviates 
0 -N 
from 1, the inhibition increases (plating efficiency approaches 0%). 
More specific examples are needed before this trend could really be 
deemed significant. Dimethoxy-substituted pyrazoles involve only two 
possible ratios. Thus, an exhaustive study might eliminate or prove the 
relevance of interaction of other groups on the activity. At the 
moment, we have not determined conclusively the effect of the remaining 
oxygen-nitrogen distance in the trimethoxy compounds. 
A comparison of 0-N-O angles as calculated from the triangulation 
process and the plating efficiency of KB cells at a test compound con-
centration of 50 µg./ml. is given in Figure 11. This graph would 
indicate that there is no correlation between the 0-N-O angles and 
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Figure 11. Relationship Between the 0-N-O Angle from 
the Triangulation Process and the 




care must be exercised in interpreting the lack of correlation of such 
data here on the basis of limited test compounds. 
Cheng reported154 a common triangulation process, consisting of one 
N atom and two 0 atoms, revealing a correlation existed among a wide 
variety of antileukemic agents of both synthetic and natural origin. 
This suggested that the arrangement of these atoms could be critical for 
binding to receptor sites on an enzyme, protein, etc.,..:!..!!. vivo. However, 
it was found that the angles in the triangulation process were not 
critical, 27 which suggested another role for the heteroatoms besides 
binding {perhaps via a charge transfer complexation). 82 
In our system, the observed biological activity of the pyrazoles 
and thiazole 111 appears to be somewhat dependent upon the oAB-N ratio, 
.-....... 0 -N 
but a relationship with the 0-N-O angle is not apparent. However, it is 
certainly plausible that steric compression generated from repulsion of 
the three oxygen atoms bonded to three adjacent sp2 carbon atoms in the 
arene ring could alter any 0-0 distance. Consequently, the basic 
length of the triangle (0-0 distance) used in the calculations might 
vary from compound to compound. This, in turn, would change the 
expected O-N-0 angle. Therefore, the 0-N-O angle cannot be predicted 
accurately which would result in what appears to be a random relation-
ship between LO-N-0 and plating efficiency. Also, there could be 
another role for the heteroatoms in addition to binding, 154 or 
the conformation at the binding site might be rather unrestricted. 
Either of these hypotheses would be difficult to substantiate with-
out an understanding of the inhibition mechanism. It is recognized that 
even in systems as simple as some of ours, additional mechanistic work 
at the molecular level is needed to determine the true cause of 
154 
inhibition. Thus, we are somewhat limited to date in our understanding 
of the role of heteroatoms in the pyrazoles in inhibiting KB cell plat-
ing, but we can infer that the heteroatom distances between oxygen and 
nitrogen atoms do have an effect on reactivity. 
Suggestions for Further Work 
The successful application of synthetic methods for the hetero-
steroids and 11 model 11 compounds herein discussed could be extended to 
the formation of similar compounds containing heterocyclic and 
trimethoxyarene functions. Sengupta and co-workers 125 report the 
preparation of the diaminopyrimidines 205 and 206 from the condensation ,...._, ~




Realizing the importance of pyrimidines in biologi'cal systems, 28 ,29 ,30 
by applying this method to the polymethoxytetralones and -phenanthrones 
one might conceivably prepare biologically active diaminopyrimidines. 
Since 1,2-benzisoxazole (207) and 4,5,6,7-tetrahydro-1,2---
benzisoxazole (208) undergo photoinduced transposition into either -
benzoxazole (209) 48 or 4,5,6,7-tetrahydrobenzoxazole (210) 48 (the latter - -
-·@=j ()) ---· cc~ 
207 209 208 
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in almost quantitative yield), it is conceivable that the same process 
could be applied to the isoxazoles 99 and 100 fo~ formation of the cor-.,......._, 
responding oxazoles. 
For a more complete study of a possible correlation between the 
methoxy-heteroatom distances and biological activity, other possible 
ortho-methoxypyrazoles 211 and 212 and the tetramethoxy derivative 213 - ___., ---
212 
should be synthesized and screened. Tetralones 215 and 216 are known _ __,, ___,, 
and could be easily prepared; 7 , 45 however, starting tetralone 214 has --
CH30 0 · CH30oo 
214 
not been reported. This tetralone might be difficult to obtain by 
similar processes due to the steric hindrance of the methoxy group 
at C(8). 
Pyridine hydrochloride is probably a commendable reagent for 
methoxy cleavage of the trimethoxy derivatives. However, it may not be 
successful on the isoxazoles due to their propensity to undergo ring 
opening. 59 Longer reaction times might be necessary for complete 
demethylation of the pyrazoles, but increased temperature might lead to 
decomposition. 
To increase water solubility in ways other than cleavage of the 
methoxy groups, it is conceivable that hydrophilic groups (i.e., 
carboxylic or sulfonic acids or sugars, such as glucose or ribose) 
could be added to the pyrazoles or the hydrochlorides of the amino-




Preparation of 3,4-Dihydro-5,6,7-1(2H)-naphthalenone (~). 132 
1,2,3-Trimethoxybenzene (16.8 g., 0.1 mole) and 3-carbomethoxypropanoic 
acid (20 g., 0.15 mole) were stirred for 2.5 hr. in 230 g. of 115% PPA, 
the temperature being maintained at 45°. The mixture was then poured 
with stirring into 500 ml. of ice and water. The granular product was 
removed by filtration, washed with H2o and 5% NaHC03, and dissolved in 
100 ml. of diethyl ether. After the ethereal solution was dried (Mgso4), 
it was concentrated to give an oil which crystallized upon standing 
aMelting points were obtained on a Thomas-Hoover capillary melting 
point apparatus and were uncorrected. 
bProton magnetic resonance spectra were taken on a Varian XL-100 
(15) high resolution NMR spectrometer using tetramethylsilane (TMS) as 
the internal standard. · 
cinfrared spectra were taken on a Beckman IR-SA spectrophotometer 
with samples as films on sodium chloride discs or in potassium bromide 
pellets. 
dlow and high resolution mass spectra were obtained on a CEC 
21-110 B double-focusing mass spectrometer. 
eElemental analyses were performed by Galbraith Laboratories, 
Knoxville, Tennessee. 
fcommercially available reagents were used without further purifica-
tion unless otherwise stated. Sodium methoxide was obtained from 
Research Organic/Inorganic Chemical Corporation, Belleville, New Jersey 
and 115% polyphosphoric acid (82.3% P2o5, guaranteed minimum) was 
obtained from FMC Corporation. 
157 
158 
(25.2 g., 0.082 mole, 86% crude). Recrystallization of the solid (hot 
hexane) gave pure methyl 4-(2 1 ,3 ',4 1-trimethoxyphenyl )-4-oxobutanoate 
(114), m.p. 48-49°, lit. 55 m.p. 48-49° (20.4 g., 0.072 mole, 72%); -
ir (KBr) µ: 5.77' (C=O), 6.02 (C=O);nmr (DCC1 3), 6 2.71 (t, 2, ~HCCH = 
6 Hz, CH2CH), 3.30 {t, 2, ~HCCH = 6 Hz, c~2co), 3.69 (s, 3, co2c~3 ), 
3.87, 3 .. 90, and 3.99 [s, 9, Ar (OC~3 ) 3], 6.71 and 7.53 [d(AB pattern), 
2, ~HCCH = 4.5 Hz, ArH]· 
A sample of 114 (9.5 g., 0.032 mole), glacial acetic acid (60 ml.), -
and palladium on charcoal (10%, 4 g.) was shaken under a H2 atmosphere 
(30-40 psi) in a Parr hydrogenation apparatus. The reaction temperature 
was maintained at ca 60°. Hydrogen uptake ceased after ca 30 min. 
(theoretical amount). The reaction mixture was cooled and filtered 
through a cake of filter aid. Solvent was removed to give crude methyl 
4-(2 1 ,3 1,4'-trimethoxyphenyl)butanoate {115) {8.6 g., quantitative) as a -
pale yellow oil. An analytical sample was obtained by distillation, 
b.p.113-114°/20-30 mm.; ir {film)µ: 3.40 {C-H), 5.75 {C=O), 6.25 {Ar), 
9.05 {OCH3); nmr {DCC1 3), 6 1.85 {m, 2, CH2c~2cH2 ), 2.34 {t, 2, ~HCCH = 
6 Hz, C~2cH2CH2 ), 2.60 [t, 2, ~HCCH ~ 7 Hz, CH2CH2c~ 2C{O)J, 2.65 {s, 3, 
co2CH3), 3.81, 3.84, and 3.87 [s, 9, Ar {OC~3 ) 3], 6.59 and 6.81 [d(AB 
pattern), 2, ~HCCH = 8 Hz, Ar~]. 
Saponification of ill {8.6 g., 0.032 mole) was achieved by boiling 
115 in 100 ml of 5% NaOH for 5 hr. The cooled basic solution was -
extracted {ether, 3x, 50 ml) and the extracts were discarded. The 
aqueous portion was acidified with HCl {6!!) and extracted (ether, 2x, 
60 ml). The ethereal extracts were dried {MgS04) and evaporated to 
give 4-(2 1 ,3 1 ,4 1-trimethoxyphenyl)butanoic acid {8.Q g., quantitative) 
as a clear oil; ir {film)µ: 2.9 (OH), 5.85 {C=O), 9.06 {OCH3), 6.25 
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(Ar); nmr (DCC1 3), o 1.95 (m, 2, CH2c~2cH2 }, 2.40 (t, 2, ~HCCH = 7 Hz, 
C~2 -co2H}, 2.63 (t, 2, ~HCCH = 7 Hz, Ar CH2}, 3.82, 3.86, and 3.88 [s, 
9, Ar (OCH3)3], 6.58 and 6.82 [d{AB pattern}, 2, ~HCCH = 8 Hz, Ar~] and 
10.98 (s, 1, C02H}. 
The crude trimethoxyphenylbutanoic acid (8.0 g., 0.032 mole} with-
out further purification was treated with 115% PPA (80 g.} with stirring 
for 45 min. at 65-70°. The dark mixture was cooled to room temperature 
and poured into 200 ml of 50/50 ice/H2o. After the mixture was 
thoroughly hydrolyzed, the product was filtered out, washed (2% NaHC03} 
and (air) dried to give crude 28. Sublimation (72-76°/0.0009 mm.} gave . ......, 
pure 28 (6.4 g., m.p. 74.5-76°, lit. 65 m.p. 74-74.5°, 84%). IR, NMR and ......... 
mass spectral analyses (Plates I, II, and Table VIII} support the· 
structure of 3,4-dihydro-5,6,7-trimethoxy-1(2!!)-naphthalenone. 
Preparation of the Oxime of 3,4-Dihydro-5,6,7-trimethoxy-1(2~}­
naphthalenone (~). 123 To a solution of 0.5 g. (0.0073 mole) of 
hydroxylamine hydrochloride in 3 ml. of water was added 2 ml. of an 
aqueous 10% sodium hydroxide solution and 0.2 g. (0.0082 mole) of the 
trimethoxytetralone 28. Just enough 95% ethanol was added to dissolve .-
the ketone. After the solution was heated on a steam bath for 15 min. 
and then cooled in an ice/H20 bath, a white precipitate formed. Filtra-
tion and drying in vacuo gave 0.18 g. (51%) of the oxime ~' m.p. 102-. 
103°. The structure of 139 is supported by IR and NMR spectra (Plates -
III and IV) along with mass spectral data (Table VIII). 
Anal. Calcd. for c13H17No4: N, 5.58. 
Found: N, 5.42. 
Preparation of the Methoxime of 3,4-Dihydro-5,6,7-trimethoxy-1(2H)-
naphthalenone (140). 127 Methoxyamine hydrochloride (0.7 g., 0.0084 mole) -
was dissolved in 3 ml. of water. Two ml. of aqueous 10% sodium 
hydroxide solution and 0.2 g. (0.00082 mole) of the tetralone 28 was ,..... 
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added. Enough 95% ethanol was added to dissolve the.tetralone. After 
heating on a steam bath for 15 min., the solution was cooled in an ice/ 
H2o bath. The methoxime !.1:Q was collected (76 mg., 35%, m.p. 55-56.5°) 
and structural characterization was achieved via IR, NMR and mass 
spectral analyses (Plates V, VI and Table VIII). 
Anal. Calcd. for c14H19No4: N, 5.28. 
Found: N, 5.04. 
Preparation of the Thiosemicarbazone of 3,4~Dihydro-5,6,7-
trimethoxy-1(2_~_}-naphthal enone (!41). 127 Trimethoxytetral one ~ (2. 0 
g., 0.0085 mole) and 0.77 g. (0.0085 mole) of thiosemicarbazide were 
added to 50 ml. of methanol. The resulting solution was boiled for an 
hour, cooled overnight,. and filtered. The white solid [m.p. 185-186° 
(decamp.), 1.6 g., 61%] is shown by IR, NMR and mass spectral data 
(Plates VII, VIII and Table VIII) to be !i!· 
Anal. Calcd. for c13H19N3o3s: N, 13.59. 
Found: N, 13.48. 
Preparation of the 2,4-Dinitrophenylhydrazone of 3,4-Dihydro-5,6,7-
trimethoxy-1(2H)-naphthalenone (136). 126 2,4-Dinitrophenylhydrazine 
- --
(0.4 g., 0.0020 mole) was added to 2 ml. of concentrated H2so4. Three 
ml. of water was added with stirring until solution was complete; then 
95% ethanol {10 ml.) was added. The trimethoxytetralone ~ (0.47 g., 
0.0020 mole) was dissolved in 20 ml. of 95% ethanol. Immediate reaction 
occurred upon mixing the two solutions and the bright red solid 
precipitate was collected by suction filtration. Recrystallization from 
ethyl acetate/95% ethanol gave 0.55 g. (66%) of pure 136, m.p. 244-245° .,,....._. 
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(lit.65 m.p. 245°). IR and NMR spectral data (Plates IX and X) support 
the structure of 136. -
Anal. Calcd. for c19H20N4o7: N, 13.46. 
Found: N, 13.44. 
Preparation of 3,4-Dihydro-2-(hydroxymethylene)-5,6,7-trimethoxy-
1(2H)-naphthalehone (ill). A mixture of 4.63 g. (0.085 mole) of sodium 
methoxide and 6.30 g. (0.085 mole) of ethyl formate in 50 ml. of 
anhydrous benzene (reagent grade, dried over Na metal) was cooled under 
N2 to 0-3° in an ice/H2o bath. 3,4-Dihydro-5,6,7-trimethoxy-1(2.!:D-
naphthalenone (_g§) (10.0 g., 0.0424 mole) was dissolved in 50 ml. of 
anhydrous benzene and slowly added through an addition funnel to the 
cooled reaction mixture (temperature between 0-3°). This yellow mixture 
was stirred (under N2) at 0-3° for 1 hr. and then allowed to come to 
room temperature for 2 hr. The reaction mixture now was a yellow gel 
which was scooped out into 200 ml. of ice and stirred until the ice had 
dissolved. The organic layer was separated and washed twice with H2o 
and once with 5% NaOH. These aqueous washings were added to the 
original aqueous layer and washed first with benzene then once with 
ether. The remaining aqueous layer was acidified (10% HCl) to pH 6.0 
and washed (ether, 3x, 50 ml.). The ether layers were combined and the 
ether was evaporated leaving a dark brown oil. The oil was dissolved 
in hot hexanes and decolorized with activated charcoal. Upon cooling, 
cubic crystals formed, which were pure !,i?. (7.75 g., 69%), m.p. 74-76°. 
A mixed m.p. with ~was taken, m.p. 55-64°. The proposed structure of 
142 is confirmed, by IR, NMR, and mass spectral analyses (Plates XIII, -
XIV, and Tables VIII and IX). 
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Preparation of 4 ,5-Di hydro-6, 7 ,8-trimethoxy-lH-b.enz [g] i ndazo 1 e 
(97) .. The hydroxymethylene compound 142 (5.1 g., 0.0193 mole) was dis-- -
solved in 50 ml. of anhydrous methanol (distilled from Mg) and 5.0 ml. 
(5.0 g., 0.16 mole) of hydrazine (anhydrous, 97+%) was added. Being 
exothermic, the mixture was stirred (under N2) for 3.5 hr. Water (80 
ml.) was added and the resulting solution was cooled overnight. Tan 
crystals formed and were filt~red out to give crude 22 (3.4 g., 68%). 
Recrystallization (benzene/hexane) gave pure 97, m.p. 94-95°. IR, NMR, 
~. 
and mass spectral analyses (Plates XV, XVI and Ta~le VIII) support the 
proposed structure of 97. -
Anal. Calcd. for c14H16N2o3: N, 10.77. 
Found: N, 10.64. 
Preparation of 4,5-Dihydro-6,7,8-trimethoxynaphth[l,2-d]isoxazole 
(~-~). To a solution of 4,4 g. (0.017 mole) of the a-ketohydroxymethylene 
compound 142 in 50 mi. of glacial acetic acid was added a solution of ,.....__ 
1.16 g. (0 .• 017 mole) of hydroxylamine hydrochloride and 1.37 g. (0.017 
mole) of sodium acetate in 4 ml. of water. The mixture was stirred 
(under N2) and heated to 1000 C for 1 hr. Cooling to room temperature 
caused deposition of a small amount of solid which was filtered off. 
The filtrate was cooled in an ice/H2o bath and water was added until 
precipitation was complete. The dark reaction mixture was filtered and 
the brown solid was washed with 5 ml. of cold H2o and air dried. The 
crude material was then sublimed (95°/7.5 x 10-4 mm.) to yield 2.9 g. 
(67%) of pure~' m.p. 92-93°. IR, NMR, and spectral analyses (Plates 
XVII, XVIII and Table XVIII) support the proposed structure of~· 
Anal. Calcd. for c14H15No4: C, 64.36; H, 5.79; N, 5.36. 
Found: C, 64.35; H, 5.88; N, 5.27. 
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Preparation of Methyl 1,2,3,4-Tetrahydro-5,6,7-trimethoxy-1-oxo-2-
naphthoate (~). Trimethoxytetralone ~ (11.1 g., 0.47 mole) was dis-
solved in 50 ml. of anhydrous dimethyl carbonate (distilled from NaH, 
b.p. 89-90°). Sodium methoxide (4.85 g., 0.090 mole) was added and 
the mixture was boiled (3 hr.). The solvent was evaporated off and 50 
ml. of water was added to the residue. After acidification {pH 6.8) 
with 25% aqueous acetic acid, the solution was extracted with ether (2x, 
30 ml.). Evaporation of the ether gave a mixture of the keto ester~ 
and starting tetralone 28. Distillation of the mixture gave 10.2 g. _,..._, 
(64%) of crude 148, b.p. 188-192°/0.4 mm., suitable for use in subsequent ,,,.__ 
reactions. Crystallization of the slightly yellow oil from methanol 
gave a pure sample of 148, m.p. 71-74°. IR, NMR, and mass spectral ---
analyses (Plates XIX, XX and Tables VIII and IX) support the proposed 
structure of 148. ---
Preparation of 4,5-Dihydro-6,7,8-trimethoxy-lH-benz[g]indazole 
{!_Q!). The crude keto ester ill (3.75 g., 0.0127 mole) was dissolved in 
5 ml. of anhydrous methanol (distilled from Mg); hydrazine (4.1 ml., 
4.1 g., 0.045 mole, anhydrous, 97+%} was added and the solution was 
heated at reflux (1 hr.). After the solution was cooled to room 
temperature, 30 ml. of water was added, and the mixture was chilled 
(ice/H20 bath) until a precipitate formed. Filtration and recrystalliza-
tion from 50/50 c2H50H/H20 gave a white crystalline product (0.58 g.), 
m.p. 74-76°. which proved on analysis [see IR, NMR, and mass spectral 
data (Plates XXI, XXII and Tables VIII and IX)} to be ~rather than 
the expected indazole 101. Upon standing for a couple of days, the 
original filtrate produced a white precipitate. Filtration and 
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sublimation (192°/0.003 mm.) of this solid gave a pure white compound, 
m.p. 235-237° (1.19 g., 34%) which, when analyzed by IR, NMR, and mass 
spectral methods (Plates XX!, XXII and Tables VIII and IX), proved to 
be the expected pyrazo 1 one 101. 
. --
Preparation of 2-Amino-5,6-dihydro-7,8,9:-trimethoxybenzo[h]-
guinazolin-4-ol (:!~). Guanidine hydrochloride (0.77 g., 0.0080 mole) 
and sodium methoxide (0.87 g., 0.016 mole) were dissolved in 40 ml. of 
absolute methanol -(distilled from Mg). The keto ester !.@ (2.34 g., 
0.00795 mole) was dissolved in 20 ml. of absolute methanol and slowly 
added to the first solution. Af.ter heating under N2 for 9 hr., the 
solvent was evaporated off and the residue was dissolved in 40 ml. of 
water. Treatment with Nuchar, followed by filtration through Celite 
filter aid, yielded a slightly brown solution. This was first washed 
with ether, cooled in_an ice/H20 bath, then acidified with glacial 
acetic acid to yield 1.035 g. of crude .!Q.1. Sublimation (186°/0.002 mm.) 
gave pure !.Qi(0.62 g., 26%) m.p. 255-257° (decamp.). NMR and IR 
analyses (Plates XXIII and XXIV) support the proposed structure of 104 
as does mass spectral data (Table VIII). 
Anal. Calcd. for c15H17N304: C, 59.41; H, 5.61; N, 13.86. 
Found: C, 59.24; H, 5.75; N, 13.72. 
Preparation of 5,6-Dihydro-2-mercapto-7,8,9-trimethoxybenzo[h]-
guinazolin-4-ol (!Q§). Thiourea (0.39 g., 0.0051 mole) and sodium 
methoxide (0.44 g., 0.010 mol~) were dissolved in 50 ml. of 2-propanol. 
After addition of the keto ester 148 (1.50 g., 0.0051 mole), the reac--
tion mixture was vigorously boiled under N2 for 24 hr. The reaction 
mixture became increasingly cloudy during the reaction time owing to the 
water formed in the reaction. Evaporation of the solvent left a dirty 
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yellow residue which was dissolved in 40 ml. of water. Extraction with 
ether afforded a pale yellow aqueous layer which, upon cooling in an 
ice/H2o bath and slow acidification with glacial acetic acid, yielded 
0.183 g. (0.00057 mole, 11.2%) of pure !Q§, m.p. 206-207° (decamp.). 
The structure of 105 is supported by IR and NMR (Plates XXV and XXVI) --
data and mass spectral data (Table VIII). 
Anal. Calcd. for c15H16N2o4s: N, 8.75; S, 10.00. 
Found: N, 8.27; S, 9.60. 
Preparation of 2,3a,4,5-Tetrahydro-6,7,8-trimethoxy-3a-methyl-3H-
benz[g]indazol-3-one (102). A three-necked, round-bottom flask fitted 
- . -
with a mechanical stirrer and Friedrich condenser was purged with 
nitrogen and dried by heating with a flame. 5,6,7-Trimethoxy-1-
tetralone (~) (10 g., 0.058 mole), 4 g. (0.089 mole) of sodium 
methoxide, and 100 ml. of anhydrous dimethyl carbonate (distilled from 
NaH, b.p. 89-90°) were added to the dry apparatus and the mixture was 
heated at reflux for 2 hr. A yellow suspension formed and was diluted 
with 200 ml. of anhydrous methanol (distilled from Mg, b.p. 64°). 
Iodomethane (10 ml., 22.7 g., 0.16 mole) was added and the reaction 
mixture was stirred at room temperature overnight. An additional 5 ml. 
of iodomethane (0.08 mole) was added, and the mixture was boiled for 
1 hr. After coming to room temperature, the brown solution was 
acidified to pH 6.5 (2 N acetic acid) and extracted three times with 
ether (30 ml. each). The ether layer was washed once with H2o. After 
the ether was evaporated, the residue was vacuum-distilled to yield 
13.35 g. (71.5%) of slightly colored methyl 1,2,3,4-tetrahydro-5,6,7-
trimethoxy-2-methyl-1-oxo-2-naphthoate (~), b.p. 160-170°/0.3-0.5 mm. 
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Structural characterization is supported by IR, NMR, and mass spectra 
analysis (Plates XXVII, XXVIII and Tables VIII and IX). 
To 13.35 g, {0.046 mole) of this keto ester @ was added 16.0 g. 
(0.50 mole) of 95% hydrazine (from Eastman Chemical Company) and 10 ml. 
of anhydrous methanol (distilled from Mg, b.p. 640), The mixture was 
heated to 50° for 1 hr. and then stirred at room temperature fo~ an 
additional 2 hr. The cooled mixture was poured onto 50 ml. of H20; a 
white precipitate formed immediately. After filtration, the crystals 
were triturated in ether, filtered out,and sublimed (172°/0.005 mm.) to 
yield 11.4 g. (84.5%) of pure !.Qg, m.p. 186-188°. IR', NMR, and mass 
spectral analyses {Plates XXIX, XXX, ~nd Table VIII) support the 
proposed structure of 102. -
Anal. Calcd. for c15H18N2o4:, N, 9.65. 
Found: N, 9.69. 
Preparation of 5,6,7-Trimethoxy-l-naphthalenebutyric Acid (~). A 
zinc (50 g., 0.76 g. at.) sheet 1/100 in. thick was cut into approx-
imately 0.25 in. by 0.5 in. pieces and washed consecutively with dilute 
HCl (2x, 100 ml.), distilled H20 (3x, 150 ml.), ar.etone (3x, 150 ml.), 
and anhydrous ether {3x, 150 ml.). The zinc was then dried in an oven 
at 100° for at least 0.5 hr. before use. 
A 300-ml. flask equipped with a condenser, mechanical stirrer, and 
N2 inlet was purged with N2 and flamed dry before 20 g. (0.31 g. at.) 
of the treated zinc, 72 ml. anhydrous, reagent-grade benzene, and 1.3 g. 
(0.0055 mole) of anhydrous HgC1 2 .were added. This mixture was stirred 
under N2 purge for 0.5 hr. Freshly distilled methyl 4-bromocrotonate 
[Aldrich Chemical Co., b.p. 32-35°/0.08-0.1 mm. (lit. 5 b.p. 83-85°/13 
mm.)] (17.6 g., 0.98 mole) and 25.0 g. (0.106 mole) of 5,6,7-trimethoxy-
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1-tetralone (28) in 20 ml. of anhydrous benzene and 50 ml. of anhydrous ,_, 
ether, along with a crystal of iodine, were added at one time to the 
reaction flask. 
After about 1 hr. of heating, the mixture turned first green and 
then red-orange in color. At 1.5-hr. intervals, 10 g. (0.15 g. at.) of 
treated zinc and 5.7 g. (0.032 mole) of methyl 4-bromocrotonate were 
added. This procedure was performed 3 times; the mixture being boiled 
and stirred under N2 the whole period. 
Heating and stirring were continued for 17 hr. after the last addi-
tion; the mixture was then cooled, poured intfr ice water, neutralized 
with acetic acid, and extracted with ether. The organic phase was 
extracted three times (50 ml. each) with 5% aqueous NH 40H, once with 
water (60 ml,), and once with saturated aqueous NaCl (40 ml.); the 
resulting solution was dried (MgS04). After filtering, the solvents 
were evaporated on an aspirator and the residual oil ~as distilled in 
vacuo. A forerun, consisting primarily of unreacted ~' distilled at 
148-160°/0.5 mm. The product, which is a viscous, red-orange oil, 
amounted to 15.2 g. (45% based on~), of crude methyl 4-(5,6,7-
trimethoxy-l,2,3,4-tetrahydro-l-naphthylidene)crotonate (~) (b.p. 
200-220°/0.5 mm.). 
Crude 217 (9.88 g., 0.031. mole) was heated to 260° with 1.78 g. of 
10% Pd/C for 6 hr. under a co2 atmosphere. The mixture was then cooled, 
diluted with ether, filtered, and evaporated. The residue was heated at 
reflux for 12 hr. with 3.8 g. (0.082 mole) of KOH in 40 ml. of 50/50 
ethanol/H20. 
The resulting hydrolyzate was diluted (H20), extracted 3 times (30 
ml. each) (ether), and acidified (dil. HCl). The acidic solution was 
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extracted 3 times with ether (40 ml. each), and the ether was evaporated 
to yield a brown solid. This solid was placed in a Soxhlet extraction 
thimble and extracted with hexanes for 11 hr. On cooling, the hexane 
solution deposited 7.65 g. (81% from crude ester lf2) of white crystals 
!1Q (m.p. 123-127°) suitable for use in the next step. A pure sample 
(m.p. 127-128°) of 130 was crystallized from hexane. IR and NMR 
spectral data (Plates XXXI and XXXII) support the reported structure for 
130. 
Preparation of 3,4-Dihydro-6,7,8-trimethoxy-1(2H)-phenanthrone 
(131). Polyphosphoric acid (30 g. of 115% PPA) was heated to 110° in a --
100-ml. beaker. Compound 11..Q. (5.8 g., 0.022 mole) was added and the 
mixture was stirred for 15 min. An additional 30 g. of PPA was added 
and the mixture was reheated to 110° and then allowed to cool with 
stirring to 60°. 
The resulting, dark-brown syrup was poured irito 150 ml. of 50/50 
.. 
ice/H20, and the dark tar-like precipitate was dissolved in benzene. 
The resulting solution was passed through a 50-g. (15 cm. by 1 cm.) 
column of alumina (Merck active aluminum oxide, neutral, activity I). 
The column was washed with additional benzene until no further material 
was eluted. Evaporation of the benzene~ vacuo yielded 2.01 g. (32.5%) 
of Jg as a light yellow powder (m.p. 135-137°) suitable for use in the 
next step. After sublimation of a small amount of the above material, 
a white, analytically pure sample of ~was obtained (m.p. 137-139°). 
IR, NMR and mass spectral analyses (Plates XXXIII, XXXIV, and Table 
VIII) support the proposed structure. 
Anal. Calcd. for c17H18o4: C, 71.33; H, 6.29. 
Found: C, 70.93; H, 6.23. 
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Preparation of 3,4-Dihydro-2-(hydroxymethylene)-6,7,8-trimethoxy-
1(2~)-phenanthrone (~). A mixture of 10 ml. of anhydrous, reagent 
benzene, 1.0 g. ;(0.023 mole) sodium methoxide, and 1.37 g. (0.0185 mole) 
of ethyl formate (under N2) was cooled to 0-3° in an ice/H20 bath. A 
solution of phenanthrone 131 (1.68 g., 0.00587 mole) in 15 ml. anhydrous 
. --
benzene was slowly added to the cooled mixture (temperature between 
0-3°). The yellow solution was stirred (under N2) at 0-3° for 1 hr. and 
then at room temperature for 3 hr. Water (60 ml.) was added, and the 
resulting two layers were separated. After washing (H20) the organic 
layer, the combined water layers were acidified with 20% aqueous HCl 
(pH 6.5). Cooling in an ice/H2o bath caused precipitation of a yellow 
solid fil (1.68 g., 91%) which was pure enough to use in subsequent 
reactions. Sublimation (140°/0.05 mm.) yielded pure~' m.p. 144.5-
146.50. IR, NMR and mass spectral data (Plates XXXV, XXXVI, and Table 
VIII) support the proposed structure for ~-
Preparation of 10,11-Dihydro-6,7,8-trimethoxy-3H-phenanthro[l,2-c]-
pyrazole (!.Q§). The hydroxymethylenephenanthrone 144 (1.55 g., 0.00495 
mole), 20 ml. of anhydrous methanol (freshly distilled from Mg), and 
1.5 ml. (1.5 g., 0.48 mole) of hydrazine (Matheson, Coleman and Bell, 
anhydrous, 97+%) were stirred and boiled (under N2) for 3.5 hr. After 
addition of 30 ml. of water, the mixture was heated for 20 min. and then 
cooled in the refrigerator. The resulting precipitate was recrystallized 
from methanol and then sublimed (155°/0.05 mm.) to yield 1.1 g. (72%) of 
pure 106 (m.p. 169-171°). IR, NMR and mass spectral analyses (Plates -
XXXVII, XXXVIll, and Table VIII) support the proposed structure of 106. 
Anal. Calcd. for c18H18N2o3: N, 9.03. 
Found: N, 9. 20. 
Preparation of 10, 11-Di hydro-7 ,8 ,9-trimethoxyphenanthro [1,2-d 1-
.i soxazol e {107). A mixture of the hydroxymethyl enephenanthrone 144 --- ·-
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(1.03 g., 0.003~ mole) and 12.5 ml. of glacial acetic acid was add~d to 
a dry flask. Hydroxylamine hydrochloride (0.24 g., 0.0034 mole) and 
.sodium ac~tate (0.27 g., 0.0034 m61e) were dissolved in 1 ml. of water 
and added to the reaction flask. The resulting solution was heated to 
100° for 1 hr. and then allowed to cool to room temperature. Distilled 
water was added with stirring, until precipitation ceased. The light 
tan solid was filtered out and washed with water. Recrystallization 
from c2H50H/acetone yielded 0.88 g. (86%) of .pure _!.Q?, m.p. 142-143°. 
IR, NMR and mass spectral analyses (Plates XXXIX, XL, and Table VIII) 
confirm the proposed structure of 107 . ..-.-
Anal. Calcd. for c18H17No4: N, 4.50. 
Found:· N, 4.41. 
1· 
Preparation of 2, 10, 11, lla-Tetrahydro-6, 7 ,8-trimethoxy-lla-methyl -
1~-phenanthro[l,2-c]pyrazol-1-one (!Q§}. A mixture of 1.46 g. (0.00511 
mole} of the phenanthrone 131, 20 ml. (21.4 g., 0.24 mole} of anhydrous ---
dimethyl carbonate (freshly distilled from NaH}, and 1.0 g. sodium 
methoxide was boiled (under N2} for 15 min. The mixture solidified and 
could not be stirred~ Anhydrous methanol (30 ml.} was ·added and the 
;" 
sol.id was broken up so stirring could be continued. Methyl iodide (3 
ml., 6.8 g., 0.048 mole} was added and the mixture was stirred at 
reflux for 1 hr. After cooling, the mixture was neutralized (CH3co2H}, 
and most of the solvents were removed with a rotary evaporator. The 
residue was diluted with water and extracted with three 30-ml. portions 
of ether. The combined ether extracts were dried (MgS04) and the ether 
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was evaporated to yield 1.55 g. (84.5%) of crude ester !..2.§. Sublimation 
(125°/0.05 mm.) yielded pure!.[§, m.p. 138-139°. IR, NMR and mass 
spectral data {Plates XLI, XLII and Table VIII) suppo.rt the proposed 
structure of 155. 
The crude ester 155 (1.03- g., 0.0029 mole), 0.9 ml. (0.9 g., 0.03 ____, 
mole) of anhydrous, 97+% hydrazine, and 5 ml. of anhydrous methanol 
{distilled from Mg) were combined and heated to 60° under N2 for 1 hr. 
The remaining solution was poured over 50/50 ice/water {30 ml.) and 
extracted with ether. Sublimation (165°/0.05 mm.) of the residue, after 
evaporation of the ether, yielded 56 mg. (32.2% from the phenanthrone 
_£!) of pure .!Q§, rn.p. 205-206°. IR, NMR, and mass spectral analyses 
{Plates XLIII, XLIV, and Table VIII) support the proposed structure of 
108. 
Anal. Calcd. fo-r c19H21N2o4: N, 8.24. 
Found: N, 8.22. 
Preparation of 3,4-Dihydro-6,7,8-trimethoxy-1(2H)-naphthalenone 
{125). 153 To a cold (5° C) solution of 180 g. (4.5 mole) of sodium ,......_ 
hydroxide in 1100 ml. of water was added 110 g. (0.647 mole) of gallic 
acid (!!?). After all of the acid had dissolved, dimethyl sulfate (295 
ml., 392 g., 3.12 mole) was added; the ice/H2o bath was removed, and 
the solution was stirred for 20 min. The solution was then boiled for 
2 hr. In order to saponify the small amount of ester produced, an 
additional 44 g. (1.1 mole) of sodium hydroxide in 66 ml. of water was 
then added, and boiling was continued for 2 hr. After cooling, the mix-
ture was acidified (dilute HCl); the precipitated trimethylgallic acid 
(118) was filtered out and washed well with cold water. Recrystalliza--
tion from water yielded 88 g. {71%) of pure 118, m.p. 165-167° (lit. 93 ___. 
172 
m.p. 1670). 
Trimethylgallic acid (118) (41 g., 0.19 mole) was heated with 50 g. ---
(0.42 mole) of thionyl chloride until the evolution of HCl and so2 
ceased (2 hr.). Benzene (100 ml.) was added and ~he mixture was cooled. 
Rotary evaporation of the solvents, followed by recrystallization (1 ml. 
benzene/100 ml. petroleum ether-b.p. 65-75°), gave 28 g. (49%) of 3,4,5-
trimethoxybenzoyl chloride(~) (m.p. 74-77°, lit. 108 m.p. 77-78°). 
Ethyl (3,4,5-trimethoxybenzoyl)acetoacetate (Jl.Q) was prepared by 
the method of Koo. 81 Sodium (31.5 g., 1.37 g. at.) was dissolved in 500 
ml. of absolute ether and 121.5 g. (0.935 mole) of ethyl acetoacetate. 
After the mixture had been stirred for 10 min., one-half of a solution 
of 1!2. (104 g., 0.45 mole) in 680 ml. of absolute ether was added drop-
wise during 30 min. The remaining one-third of the sodium ethoxide 
solution was added 20 min. later. Ten min. later the rest of the solu-
tion of acid chloride was added, again over a 30-min. period. Stirring 
was continued overnight. A thick paste was collected by suction filtra-
tion and dissolved in 1500 ml. of water, and the resulting solution was 
acidified (pH~5) (temp. between 0-5°). Recrystallization from aqueous 
ethanol provided 80 g. (55%) of ethyl (3,4,5-trimethoxybenzoyl)-
acetoacetate (~) (m.p. 78-81°, lit. 81 m.p. 83-85°) suitable for use in 
the next step. 
A mixture of 60 g. (0.165 mole) of finely ground 120 and 100 g. ----
(1.89 mole) of ammonium chloride was placed in a large flask; a homo-
geneous suspension resulted after the gradual addition of 500 ml. of 
warm water (35°) with shaking. Another 2000 ml. of water (35°) was 
added all at once, followed by 500 ml. of 15% aqueous ammonia. Most of 
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the starting material dissolved when the mixture was shaken vigorously; 
that which remained was crushed by a flattened glass rod. After 10 min., 
the mixture was ~hilled rapidly by adding ice and placed in the refrig-
erator for 2 hr. The colorless solid was collected and dried to yield 
45 g. (85%) of ethyl (3,4,5-trimethoxybenzoyl)acetate- (121), m.p. 88-89° -----
(lit. 81 m.p. 93-94°}. 
Sodium (3.5 g., 0.15 g. at.} was dissolved in 250 ml. of absolute 
ethanol with stirring. While the solution was yet warm (40°}, 28.2 g. 
(0.10 mole) of 121 was added. ·After stirring for 15 min., the solution --
was cooled in an ice/H2o bath. Ethyl bromoacetate (6.0 g., 0.038 mole) 
was added and the solution was stirred for 1 hr. An additional 12.0 g. 
(0.0755 mole} of ethyl bromoacetate was added and the solution was 
stirred overnight. The mixture was cooled again, diluted with water, 
acidified (50% HCl), and extracted with ether. The ethereal extracts 
were washed twice with 100 ml. of H20 and dried (MgS04); the ether was 
evaporated leaving a pale yellow oil. This oil was boiled in 250 ml. 
of 20% aqueous sulfuric acid for 45 hr. After cooling, the mixture was 
extracted with ether, the solvent was removed, and the residue was 
boiled with 200.ml. of 5% sodium hydroxide solution for 1 hr. Acidifi-
cation of the filtrate (after filtration} produced 24 g. (90%) of 
S-(3,4,5-trimethoxybenzoyl}propionic acid (123), m.p. 117-119° (lit. 66 
--.; 
m.p. 121-122°}. This process was repeated and the yield of acid was 
slightly increased (26 g., 97%). 
The acid~ (50 g., 0.19 mole}, 500 ml. of glacial acetic acid, 
and 6.0 g. of 10% palladium on charcoal were shaken under H2 atmosphere 
(30-40 psi) in a Parr hydrogenation apparatus (temperature.£! 60°). 
After hydrogen uptake ceased, the mixture was cooled and filtered 
through a cake of filter aid. Solvent was removed with a rotary 
evaporator. 
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The crude 4-(3 1 ,4 1 ,5 1-trimethoxyphenyl)butanoic acid (.!f.1) was 
added to 500 g. of 115% PPA, and the resulting mixture was heated (65-
700) and stirred for 45 min. A dark mixture formed and was cooled to 
room temperature and poured into 1000 ml. of 50/50 ice/H20. After the 
mixture was thoroughly hydrolyzed, the product was filtered out, washed 
(2% NaHC03) and air dried to give crude 3,4-dihydro-6,7,8-trimethoxy-
1(2Ji)-naphthalenone (]1_§). Sublimation (110 /0.01 mm.) gave pure !f§ 
[23.7 g. (53% from gg), m.p. 118-121°, lit. 65 m.p. 125°] IR, NMR and 
mass spectral analyses (Plates XLV, XLVI, and Table VIII) support the 
structure of 125. --
Preparation of the 2,4-Dinitrophenylhydrazom~ of 3,4-Dihydro-
6, 7 ,8-trimethoxy-1(2_~_)-naphtha1 enone OE). 6, 7 ,8-Trimethoxy-1-
tetra lone (!1§) (0.172 g., 0.00073 mole) was dissolved in 10 ml. of 0.10 
M solution of 2,4-dinitrophenylhydrazine50 (prepared by dissolving 2.0 g. 
of 2,4-dinitrophenylhydrazine in 50 ml. of 85% phosphoric acid, heating, 
cooling and adding 50 ml. of 95% ethanol). After heating on a steam 
bath for 15 min., the mixture deposited a bright-red solid and was 
filtered. Recrystallization of the solid from 95% ethanol gave 0.128 g. 
(31%) of pure 137, m.p. 204-205°. The structure of 137 is supported by -- ........., 
IR and NMR spectral data (Plates XLVII and XLVIII). 
Anal. Calcd. for c19H20N4o7: N, 13.46. 
Found: N, 13.41. 
Preparation of 3,4-Dihydro-2-(hydroxymethylene)-6,7,8-trimethoxy-
1(2H)-naphthalenone (~). Sodium methoxide (1.4 g., 0.0031 mole), 
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ethyl formate (1.56 g., 0.0215 mole), and 10 ml. of ahhydrous benzene 
were cooled under N2 to 0-3° via an ice/H2o bath. A solution of 2.5 g. 
{0.0106 mole) of 6,7,8-trimethoxy-1-tetralone (.J.E§) in 40 ml. of 
anhydrous benzene was added to the cooled mixture and immediately the 
mixture turned yellow, then green, and finally orange-yellow. The 
mixture was stirred under N2 at 0-3° for 1 hr., and overnight at room 
temperature. The reaction mixture was then poured into 40 ml. of ice/ 
H2o and stirred until the ice had dissolved. The organic layer was 
separated and washed with H20 {2x, 25 ml.) and 5% NaOH (lx, 25 ml.). 
The aqueous layers were combined and washed with benzene {lx, 50 ml.) 
and finally with ether. Acidification with 10% HCl and cooling produced 
2.42 g. of crude 143. Recrystallization from hexane, followed by -
sublimation (71°/0.02 mm.), yielded 1.12 g. {38.5%) of pure~' m.p. 
69-71°. The structure proposed for ~ is supported by NMR,~ IR, and 
mass spectra (Plates XLIX, L, and Tables VIII and IX). 
Preparation of 4 ,5-Di hydro-7 ,8 ,9-trimethoxy-lH-benz [g )i ndazol e 
(~). The hydroxymethylene compound~ (5.0 q., 0.019 mole) was dis-
solved in 20 ml. of anhydrous methanol (distilled from Mg}; 6.8 g. 
(0.21 mole) of 95% hydrazine {from Eastman Chemical Company} was added 
and the resulting solution was heated {50°) for 2 hr. After returning 
to room temperature, the solution was stirred overnight. The resulting 
brown solution was poured into 40 ml. of 50/50 ice/H2o and stirred until 
a precipitate formed. Isolation of the tan solid by filtration, fol-
lowed by sublimation {150°/0.2 mm.} and recrystallization from methanol, 
gave 1.3 g. {26%) of pure 98, m.p. 159-161°. Structural characteriza-
tion is supported by IR, NMR {Plates LI and LII} and mass spectral 
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values (Table VIII). 
Anal. Calcd. for c14H16N203: N, 10.77. 
Found: N, 10.93. 
Preparation of 4,5-Dihydro-7,8,9-trimethoxynaphth[l,2-d]isoxazole 
(100). The hydroxymethylene compound 143 (2.2 g., 0.0084 mole) was 
~ --..... 
dissolved in 25 ml. of glacial acetic acid, and a solution of 0.69 g. 
(0.0084 mole) of sodium acetate and 0.58 g. (0.0084 mole) of hydroxyl-
amine hydrochloride in 2 ml. of water was added. The resulting solution 
was heated (lOOO) under N2 (1 hr.). After cooling, the mixture was 
filtered to remove the solid that had formed in trace amount. Addition 
of water to the filtrate gave crude .!QQ which was sublimed (l000/0.15 
mm.) and gave 1.2 g. (55%) of pure 100, m.p. 128-130°. IR, NMR, and ......._. 
mass spectral data (Plates LIII, LIV and Table VIII) confirm the 
proposed structure of 100. ---
Anal. Calcd. for c14H15No4: N, 5.36. 
Found: N, 5.26. 
Preparation of 2,3a,4,5-Tetrahydro-7,8,9-trimethoxy-3a-methyl-3H-
benz[g] indazol-3-one (!.Q~). 6,7 ,8-Triinethoxy-1-tetralone (fil) (2.5 g., 
0.0106 mole) and 1.0 g. (0.0227 mole) sodium methoxide were dissolved in 
25 ml. of anhydrous dimethyl carbonate (distilled from NaH). This mix-
ture turned yellow, then orange-red, and finally brown within 10 min. 
Heating was initiated and the brown mixture was boiled under N2 for 2 
hr. The mixture was cooled (ice/H20 bath) before adding 25 ml. of 
anhydrous methanol and 1.5 ml. (3.2 g., 0.022 mole) of methyl iodide. 
After stirring 1 hr. at 50, the mixture was further stirred under N2 
overnight at room temperature. An additional 1.0 ml. (3.2 g., 0.022 
mole) of methyl iodide was added and the mixture was boiled (1 hr.). 
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After cooling, the mixture was acidified (25% aqueo~s CH3co2H}; solvents 
' were removed on a rotary evaporator. Water (25 ml.} was added to the 
residue, and the solution was extracted (ether, 3x, 25 ml.}. Evapbra· 
tion of the ether left crude ester~' a slightly colored oil, which 
crystalized upon standing. Recrystallization from c2H50H/H20 and 
sublimation (95°/2 mm.} gave pure ~ (1.56 g., 48%) ~ m.p. 82~84°. IR, 
NMR, and mass spectral analyses (Plates LV, LVI and Tables VIII and IX} 
support the proposed structure of methyl 1,2,3,4-tetrahydro-6,7,8-
trimethoxy-2-methyl-1-oxo-2-naphthoate (~}. 
The keto ester ~ (1.35 g., 0.0044 mole} was dissolved in 2 ml. of 
anhydrous methanol (distilled from Mg}, and 1.4 g. (0.044 mole} of 
hydrazine (anhydrous, 97+%} was added. After heating (70°} the solution 
30 min. under N2, a solid formed. Water (7 ml.} was added and the mix-
ture was cooled (ice/H2o bath). Isolation of the solid by filtration 
followed by sublimation (196°/0.003 mm.} gave 1.15 g. (90% from keto 
ester) of pure 103, m.p. 224.5-225°. Support for the structure of 103 
~ _....._,. 
is provided by IR, NMR, and mass spectral data (Plates LVII, LVIII and 
Table VIII}. Peak matching is shown in Table IX. 
Preparation of Methyl 1;2,3,4-Tetrahydro-6-methoxy-1-oxo-2-
naphthoate (![g}. 6-Methoxy-1-tetralone (~) (8.7 g., 0.0494 mole), 
4.0 g. (0.074 mole) of sodium methoxide, and 40 ml. of anhydrous 
dimethyl carbonate (distilled from LiH, b.p. 89-90°) were mechanically 
stirred (under N2) and boiled for 3 hr. Solvent was removed by evapora-
tion and the residue was dissolved in ca 30 ml. of water. Acidification 
(pH ca 6) with 25% aqueous acetic acid and cooling in ice/H20 produced 
a slightly tan solid. Filtration and drying in vacuo gave crude 150. - .,,...__ 
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Recrystallization from methanol gave 8.75 g. (76%} of pure !.2_Q, m.p. 87-
890 (lit. 74 m.p. 88-89°). IR, NMR and mass spectral analyses (Plates LIX, 
LX and Tables VIII and IX) support the proposed structure of 129. 
Preparation of 2-Amino-5,6-dihydro-8-methoxybenio[h]guinazolin-4-
Q}_ (!§j.). B-Keto ester !2_9 (2.14 g., 0.00915 mole) was dissolved in 
75 ml. of anhydrous methanol (distilled from Mg); guanidine hydrochloride 
(0.96 g., 0.010 mole) and sodium methoxide (1.08 g., 0.02 mole) were 
added and the mixture was boiled under N2 (4 hr.). After cooling over-
night, the solvents were removed (rotary evaporation). When aqueous 5% 
NaOH (100 ml.) was added, a blue solid formed which, after sublimation, 
proved to be starting tetralone 132. The filtrate was treated with --
Nuchar, filtered, and acidified (50/50 CH 3co2H;H20) to pH 6.3. Cooling 
(ice/H20 bath) produced a fine grey solid; recrystallization from 50/50 
DMSO/CH30H and sublimation (230°/0.006 mm.) gave 600 mg. (27%) of pure 
151, m.p. 325-327° (dee.). IR, NMR and mass spectral analyses (Plates ----
LXI, LXII and Table VIII) confirm the proposed structure of 151 . .,...._ 
Anal. Calcd. for c13H13N3o2: N, 17.28. 
Found: N, 17.28. 
Preparation of 5,6-Dihydro-2-mercapto-8-methoxybenzo[~guinazolin-
4-ol (152). The keto ester 150 (2.14 g., 0.00915 mole) was added to a -- --- ___, 
solution of thiourea (1.14 g., 0.015 mole) and sodium methoxide (0.81 g., 
0.015 mole) in 50 ml. of anhydrous methanol (distilled from Mg). After 
boiling under N2 (4 hr.), the mixture was stirred overnight. Evapora-
tion of the solvents left a dark residue which was dissolved in 10% 
NaOH, treated with Nuchar, and filtered through filter aid. Acidifica-
tion of the filtrate with 50/50 CH3co2HJH2o produced a powdery solid. 
Recrystallization (50/50 DMSO/CH30H) followed by sublimation (228°/0.006 
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mm.) gave 0.283 g. (12%) of pure 152, m.p. 290-294° (dee.). Structural .-..... 
support for !5.1 was provided by IR, NMR and mass spectral analyses 
(~lates LXIII, LXIV and Table VIII). 
Anal. Calcd. for c13H12N2o2s: N, 10.76; S, 12.30. 
Found: N, 10.89; S, 12.03. 
Attempted Preparation of 3-Methoxyphenethyl Bromide (!.~.§). 20,l46 
Utilizing the entrainment method for making Grignard reagents, 103 ,146 
17.3 g. (0.71 g. at.) of magnesium metal turnings and 50 g. (0.35 mole) 
of !D_-chloroanisole (~)were combined in 200 ml. of anhydrous ether. A 
solution of ethylene bromide (66.7 g., 0.35 mole) and 150 ml. of 
anhydrous ether was slowly added (rv 1 drop/12 sec.) through a dropping 
funnel to the original mixture. After the solution was boiled gen~ly 
overnight, 350 ml. of anhydrous benzene was added and the ether was dis-
tilled off. The reaction flask was cooled completely to 0-5° before a 
solution of 15.4 g. (0.35 mole) of ethylene oxide in 100 ml. of anhydrous 
ether was added (rv 1 drop/5 sec.) through a dropping funnel to the 
Grignard. After all of the ethylene oxide solution had been added, the 
mixture was stirred at 0-5° for 1 hr., allowed to reach room temperature 
for 0.5 hr., and then boiled for 0.75 hr. The reaction mixture was 
again cooled to 0-5° and an additional 5.3 g. (0.12 mole) of ethylene 
oxide, dissolved in 30 ml. of cold ether, was slowly added (rv 1 drop/5 
sec.). Again the reaction mixture was stirred for 1 hr. at 0-5°, and 
then boiled for 20 min. After cooling to room temperature, the whole 
reaction mixture was poured onto 400 ml. of 50/50 ice/H20 with stirrinq. 
The organic layer was decanted off, washed with H2o (2x, 200 ml.), and 
dried (MgS04). The aqueous layer from the reaction mixture was filtered; 
the filtrate was extracted with ether (lx, 150 ml.) and the ether layer 
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was dried (MgS04). The solvents from the combined organic layers were 
removed via a rotary evaporator, and the residue was fractionally dis-
tilled in vacuo. Fraction I (24.8 g., 49%, b.p. 31-35°/1.7-2.5 mm.) 
proved by GLC (SE-40 column) to be primarily B-anisylethyl alcohol 0.§.Z) 
with an impurity(~ 20% of starting material, 1:.2§). 
In the method of Buchta and Bayer, 20 crude 157 (13.6 g., 0.173 ,,..._, 
mole) was dissolved in 30 ml. of absolute cc1 4 and cooled to 0° in an 
ice/H2o bath. Phosphorus tribromide (15.8 g., 0.058 mole) was added 
over a 1-hr. period while keeping the reaction temperature around 0°. 
After all of the PBr3 was added, the mixture was stirred at 0° for 4 hr. 
and then stirred 20 min. at room temperature. The mixture was poured 
over 50 ml. of 50/50 ice/H20 and stirred until the ice had all melted. 
Following separation of the two layers, the organic layer was washed 
with sat. NaHC03 (2x, 20 ml.), H20 (lx, 30 ml.) and dried (MgS04). 
Evaporation of the solvents left a brown residue. Fractional distilla-
tion on the spinning band distilling column failed to separate product 
158 from the alcohol 157 as deduced from GLC analysis. ---- -
Attempted Preparation of 7-Methoxy-1,2,3,4,9,lO-hexahydro-
phenanthren-1-one (166). By means of the Reformatsky reaction via the 
method of Stork130 , methyl 4-(6-methoxy-1,2,3,4-tetrahydro-1-
naphthylidene)crotonate was prepared by first washing 141 g. (2.27 g. 
at.) of zinc metal, 0.25 in. by 0.5 in. pieces, with dilute HCl, water, 
acetone, and ether. The zinc was then dried in an oven (100°) for at 
least 0.5 hr. prior to use. To 56.5 g. (0.866 mole) of preconditioned 
zinc pieces in 210 ml. of anhydrous benzene was added 3.8 g. (0.016 
mole) of dry mercuric chloride. After the mixture had been stirred 
(under N2) for 0.5 hr. a solution of 56.1 g. (0.319 mole) of 
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6-methoxy-1-tetralone (132) and 52 g. (0.29 mole) of methyl 4-bromo-
~
crotonate in a mixture of 50 ml. of anhydrous benzene and 150 ml. of 
anhydrous ether was added all at once, followed by a crystal of iodine. 
Since no exothermic reaction took place immediately, the mixture was 
heated to boiling. After boiling for 2 hrs., additional portions of 
zinc (28.2 g., 0.432 mole) and bromo ester (17.3 g., 0.097 mole) were 
introduced. This was repeated at 1.5-hr. intervals until three addi-
tional portions had been added. Boiling was continued for 17 hr. 
after the last addition. The bright orange mixture was then cooled and 
poured on ice. The resulting mixture was acidified with acetic acid and 
extracted (ether, 2x, 150 ml. each). The organic solution was washed 
with 5% aqueous ammonia (3x, 60 ml. each), H20 and saturated salt solu-
tion. Evaporation of solvents was accomplished with a rotary evaporator, 
and the bright red residue was distilled in vacuo. A forerun (b.p. 
145-165°/1 mm.) consisted of unchanged 6-methoxy-1-tetralone (33 g.). 
The ester !.21 was collected (b.p. 180-186°/1.5 mm.) as a viscous yellovJ 
oil (27.6 g., 0.106 mole, 33.4%). 
A solution of 18.0 g. (0.0695 mole) of the ester ~dissolved i.n 
300 ml. of absolute ethanol containing 3 ml. of glacial acetic acid was 
hydrogenated in a Parr hydrogenation apparatus at atmospheric pressure 
and room temperature in the presence of 15 g. of freshly prepared Raney 
Ni catalyst, w-2. 99 •144 After 20 min., hydrogen uptake ceased and the 
catalyst was removed by filtration through filter aid (the catalyst was 
deactivated with 10% HCl). The slightly yellow filtrate was added to 
15 g. (0. 15 mole) of potassium hydroxide dissolved in 1125 ml. water. 
The mixture was boiled under N2 for 3 hr. and the alcohol was removed 
by rotary evaporation. The aqueous alkaline solution v1as extracted 
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three times (ether, 50 ml. each), made strongly acidic with cone. HCl, 
and then extracted three times (ether, 50 ml. each). The ether extracts 
were washed with water and dried (MgS04); the ether was evaporated to 
leave a light tan solid (15.9 g.), m.p. 66-75° C. This solid was trans-
ferred to a Soxhlet extractor and extracted for 12 hr. (petroleum ether, 
b.p. 65-75°). Upon cooling, a white crystalline material precipitated 
(8.4 g., m.p. 74-75°); its identity was confirmed by IR, NMR and mass 
spectral analyses as 4-(6-methoxy-1,2 ,3 ,4-tetrahydro-1-naphthyl) butyri c 
acid (168) (lit. 144 m.p. 76-78°) rather than the expected 4-(6-methoxy-,__, 
1,2,3,4-tetrahydro-1-naphthylidene)butyric acid (l§.§) required for the 
cyclization to 1-oxo-7-methoxy-1,2,3,4,9,10-hexahydrophenanthren-1-
one (166). Several attempts to prepare the correct acid 165 gave only ---- ~ 
the undesired saturated acid 168. 
0 
II 
Spectral data for 168 are: ir (KBr) µ: 3.30-3.80 (-OH), 6.04 (-C-), 
6.35 (Ar stretching), 9.80, 11.75, 12.08, 12.38 (Ar C-H vibrations); 
nmr (DCC1 3) o, 1.5-1.9 {m, 8, CH2c~2CHR), 2.40 (m, 2, C~Ar), 2 .. 75 (m, 3, 
CH2CHRCH 2 and Ctl2co2H), 3.78 (s, 3, -0Ctl3), 6.60, 6.74, and 7.08 (m, 3, 
Ar-H); mass spectrum,~/~ (70 ev) (rel. Intensity), 115 (24), 128 (18), 
146 (17), 158 (21), 161 (100), 162 (38), 248 (28, molecular ion). 
Attempted Preparation of 3,4-Dihydro-1(2H)-naphthalenone-5,6,7-
triol (~). Trimethoxytetralone 28 (1.0 g., 0.0042 mole) was heated 
to 180° for 2 hr. in the presence of 2.25 g. (0.051 mole) of freshly 
fused pyridine hydrochloride. After cooling, the reaction mixture was 
dissolved in 40 ml. of 5% HCl. Following extraction with ether (5x, 
20-ml. portions), the combined ether layers were washed (lx, 40 ml. H20) 
and dried (MgS04); the ether was evaporated leaving 0.40 g. of greenish 
residue. Sublimation (168°/0.1 rmn.) yielded 0.15 g. (31%) of slightly 
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impure 169, m.p. 210-211°; ir (KBr) µ: 2.90-4.10 (OH), 6.11 (C=O); nmr .......__ 
(acetone-~6 ), 8 1.88-2.16 (p, 2, JHH = 6 Hz, CH 2c~ 2cH 2 ), 2.38-2.56 (t, 
2, JHH = 6 Hz, ~~2 ), 2.72-2.92 [t, 2, JHH = 6 Hz, c~2 C(O)], 3.10 (s, 
1, O!j_), 7 .11 (s, 1, Ar-!j_), 7. 97 (s, 2, O!j_). 
Anal. Calcd. for c10H10o4: C, 61.68, H, 5.15. 
Found: C, 60.92, H, 5.11. 
Preparation of 3,4-Dihydro-1(2H)-naphthalenone-6,7,8-triol (]l9). 
Dry pyridine hydrochloride (2.25 g., 0.015 mole) was freshly fused under 
nitrogen before 1.0 g. (0.0042 mole) of 6,7,8-trimethoxy-l-tetralone 
(125) was added. After heating (180°) for 2 hr., the reaction mixture ----
was cooled and 40 ml. of 5% HCl was added. A precipitate formed and was 
filtered out. Sublimation (170°/0.l mm.) gave 0.17 g. (20.9%) of pure 
170, m.p. 185-186°; ir (KBr) µ: 2.88-3.80 (OH), 6.12 (C=O); nmr (acetone----
96), 8 1.84-2.16 (p, 2, JHH = 6 Hz, CH2c~2cH2 ), 2.48-2.65 (t, 2, JHH = 6 
Hz, C~2 ), 2.70-2.88 [t, 2, JHH = 6 Hz, C~2C(O)J, 3.00 (s, 1, O!j_), 6.28 
(s, 1, Ar!j_), 8.00 (s, 1, O!j_), 12.79 (s, 1, O!j_). 
Anal. Calcd. for c10H10o4: c, 61.86, H, 5.15. 
Found: C, 61.80, H, 5.10. 
Attempted Preparation of 4,5-Dihydro-lH-benz[g]indazole-6,7,8-
triol (171). Pyrazole 91. (1.0 g., 0.00384 mole) was added to 3.0 g. ----
(0.026 mole) of freshly fused pyridine hydrochloride and heated (180°) 
for 2 hr. under nitrogen. A precipitate formed as 40 ml. of 5% HCl 
was added. After cooling, the solid was filtered out, then sublimed 
(210°/0.l mm.) to give 0.30 g. (35.8%) of partially cleaved 97 (crude), ---
m. p. 235-240° (dee.); ir(KBr) µ: 2.90-3.25, 3.45-4.20 (OH), 6.25 (C=N); 
nmr (acetone-~6 ), 8 2.42-2.80 (m, 4, c~2c~ 2 ), 3.78 (s, 3, oc~ 3 ), 6.70 
(s, 1, Ar!j_), 7.27 (s, 2, O!j_), 7.37 (s, 1, C!j_). 
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Attempted Preparation of 4,5-Dihydronaphth[2,l-d]isoxazole-6,7,8-
triol (172). Isoxazole 97 (1.7 g., 0.0065 mole) was heated (180°) fo~ 
-- ..-..J 
2 hr. in the presence of 3.5 g. (0.030 mole) of freshly fused pyridine 
hydrochloride. As the reaction progressed, the mixture darkened until 
it was black after 2 hr. Addition of 40 ml. of 5% HCl did not dissolve 
the black tar. Attempts at sublimation failed to yield any product. 
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Thiosemicarbazone of 3,4-Dihydro-5,6,7-trimethoxy-1(2H)-naphthalenone (141) 
- ·---
Solvent .• CF3C02H 
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2,4-Dinitrophenylhydrazone of 3,4-Dihydro-5,6,7-trimethoxy-1(2H)-naphthalenone (136) 
,' ' - ,__._,. 
Solvent ••• DCCl3 
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Hydrazone of 3,4-Dihydro-5,6,7-trimethoxy-1(2!:!)-naphtha1enone (~~) 
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Methyl 1,2,3,4-Tetrahydro-5,6,7-trimethoxy-1-oxo-2-naphthoate {148) 
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WAVflENGTH IN MICRONS 
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10, 11-Di hydro-6, 7 ,8-trimethoxy-3H-phenanthro [1,2-~] pyrazo 1 e (!Q§) 
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10, 11-Di hydro-7 ,8 ,9-trimethoxyphenanthro [1,2-g] i soxazo le (107) 
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Methyl 1,2,3,4-Tetrahydro-6,7,8-trimethoxy'-2-methyl-1-oxo-2-phenanthrenecarboxylate (~) 
Solvent ••• DCCl3 
S.W •.•• 1000 Hz 
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F.B ...•• 2 Hz 
S.O ••. 83701 Hz 
R.F ••• 61 dB 
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3,4-Dihydro-6,7,8-trimethoxy-1(2H)-naphthalenone (125) 
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